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CHAPTER 1. 
1. Introduction 
Although the major part of cardiovascular (CV) events in childhood are characterized by 
congenital heart disease (CHD), there is a wide spectrum of CV events that start from 
conventional CV risk factors that are present also in children, arriving to atherosclerotic 
events, most of all in some particular populations (i.e. patients with rheumatic diseases, 
obese patients, patients with HIV, patients with kidney disease, etc.). On the other hand, 
the large use of some pharmacological agents can play a role in the development of CV 
events, generally atherosclerotic. This aspect, that normally involve adult patients, could 
affect also children. There is also a spectrum of causes related to heart failure, that 
generally involve adults, but that can start from childhood. However, CHD remain the 
most common CV presentation in childhood. Thanks to progress in surgery, a great part of 
these patients arrives to adulthood, where they are included in another classification called 
grown-up congenital heart disease (GUCH). 
1.1. Cardiovascular diseases could start from childhood 
Atherosclerotic CV disease remains the leading cause of morbidity and mortality 
worldwide, but manifest disease in childhood and adolescence is rare (1). By contrast, risk 
factors responsible of atherosclerosis are present since childhood. The autopsy findings in 
The Bogalusa Heart Study and Pathobiological Determinants of Atherosclerosis in Youth 
showed a strong relationship of vascular disease to traditional CV risk factors (2,3). This  
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observation provided irrefutable evidence of the importance of act on modifiable CV risk 
factors, such as cigarette smoking, hypercholesterolemia, hypertension, obesity and 
diabetes (4–6). On the other hand, there are several emerging CV risk factors, that have not 
been widely studied (i.e. C reactive protein, homocysteine, small dense low density 
lipoprotein, oxidized low density lipoprotein, apoliproteins, lipoprotein a, fibrinogen) (7), 
and also some non-modifiable atherosclerosic risk factors (i.e. age, gender, CV family 
history), that don’t permit to reduce completely the CV burden in childhood, resulting in a 
great CV risk in adulthood. Considered a relatively recently discovered CV risk factor, 
common carotid artery intima-media thickness (IMT) measured by ultrasound imaging, 
represents a marker of preclinical atherosclerosis, correlating with vascular risk factors (8–
10), relating to the severity and extent of coronary artery disease (8). Several studies, in 
particular in some specific conditions (i.e. obesity, HIV), have shown an increase of IMT 
also in childhood (11,12). Finally, a more recent parameter of CV risk has been studied, 
epicardial adipose tissue (EAT), that is part of the visceral fat deposited within the 
pericardic sac around the heart. EAT shares a common embryological origin with the intra-
abdominal visceral adipose tissue and, as such, it is a metabolically active adipose tissue 
(13,14). Hence, although EAT represents only 1% of the total body fat mass, it may be 
important in the pathophysiology of CV disease, in particular in obese patients and in HIV 
patients (13,14). Well known is the role of EAT in adult patients, instead weak is known 
about its possible role in CV risk in childhood, in particular in HIV young patients. These 
CV markers play an important role in a subclinical atherosclerosis, which can lead to  
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coronary artery disease. For this reason, very important is also the role of imaging 
techniques to detect very early subclinical coronary artery disease, to treat as soon as 
possible CV disease, for a better prognosis. There is also a large part of iatrogenic CV 
events, that could start from childhood, but that generally are more frequent in adult 
patients, due to the large use of some medications in adulthood. In particular, in patients 
with rheumatic diseases, that could be present also in childhood, there is a wide use of non-
steroid anti-inflammatory drugs (NSAIDs), that have many side effects, not only on 
gastrointestinal system, but also at cardiac level (15), increasing the risk of ischemic 
disease and heart failure. Although heart failure is typically an “older disease”, there are 
many situations related to its development that can start since childhood. First of all, many 
CHD could lead to heart failure, also HIV infection could be related to left ventricular 
dysfunction, but there are also many other causes of heart failure development, that go 
from some CV risk factors implicated not only in atherosclerotic events (i.e. diabetes) (16–
18), to a deficiency of some factors (one of the most important is vitamin D) (19). There 
are two points to define in these cases: first of all, these two causes can start since 
childhood, leading to CV events very early, and secondary, there are new treatment 
approach for diabetes (i.e. inhibitors of sodium glucose co-transporter-2, and glucagon-like 
peptide-1 agonists) (16–18) and also vitamin D supplementation (20,21), that could be 
responsible of a regression of CV events in these patients.     
1.2. Congenital heart disease: from childhood to GUCH 
CHD is the most common cause of major congenital anomalies, and 28% of all major  
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congenital anomalies consist of heart defects (22,23). Reported birth prevalence of CHD 
varies widely among studies worldwide. The estimate of 8 per 1,000 live births is generally 
accepted as the best approximation (22,24). A reliable classification of CHD should be the 
one that define a cyanotic pattern, or ductal-dependent classification, considering an 
important role of ductus arteriosus in the survival of these patients. In the group of 
congenital heart disease, there are also some known mutations, that involve the heart, 
leading to some pattern of cardiomyopathy that sometimes are incompatible with survival. 
One of these are the mitochondrial disorders, which are generally associated with 
congenital hypertrophic cardiomyopathy, with a fatal prognosis. Without a treatment, most 
defects of moderate or great complexity have a bleak prognosis (25). Thanks to the 
progress in cardiac surgery, since many years, a great part of patients born with CHD, 
reach adulthood, creating a completely new and steadily growing patient population: 
patients with grown-up congenital heart disease (GUCH) (22). It is estimated that about 
90% of affected children are expected to survive to adulthood (26), with an estimated 
prevalence of CHD of 4 per 1,000 adults (27). Patients with GUCH often need long-term 
expert medical care and healthcare-related costs are high (28). In fact, it is recognized that 
CHD is associated with lifelong comorbidity that affect healthcare costs. The impact of 
ongoing disease burden includes atrial arrhythmias, pulmonary hypertension, arterial 
hypertension, heart failure, cerebrovascular events, coronary events, and a repeated need 
for surgery, which results in significant increase in health services utilization during 
childhood, transition years, adulthood, and geriatric age group (29). A particular mention  
10 
 
 
 
 
 
is due to pulmonary hypertension, that is present in most part of shunt-defects, and that is 
responsible of a bad prognosis in these patients and arterial hypertension, that is a common 
complication in patients with coarctation of the aorta (CoA), and that worsen the prognosis 
in these patients. 
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Synopsis 
Heart failure is a clinical syndrome characterized by left ventricular dysfunction and/or 
elevated intracardiac pressures, with a prevalence of about 1 – 2%. In the last decades, 
many metabolic disorders have been studied as linked with heart failure, in particular 
glucose metabolism abnormalities. Diabetes mellitus and insulin resistance are strictly 
related with heart failure, with a bidirectional link, where each one can influence the other. 
The aim of this review is to report the role of glucose metabolism abnormalities in the 
development of HF, defining the epidemiology, and assessing pathophysiology and 
prognosis of HF related to glucose metabolism disorders. 
 
Key words: Heart failure; Glucose metabolism abnormalities; Diabetes mellitus; Insuline 
resistance; Hyperglycemia; Insulin sensitivity. 
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Key points 
 Heart failure is a clinical syndrome characterized by left ventricular dysfunction and/or 
elevated intracardiac pressures, with a prevalence of about 1 – 2% 
 There are several factors involved in HF development, that go from ischemic heart disease 
to metabolic disorders, passing through genetic etiology 
 Although the most known cardiac nosological entity related to glucose metabolism 
disorders is diabetic cardiomyopathy, insulin resistance is a very frequent finding among 
HF patients 
 the homeostasis model assessment (HOMA) index has proved to be robust and reliable tool 
for the assessment of insulin resistance 
 Heart failure can be considered the major cause of hospitalization in patients with glucose 
metabolism abnormalities 
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Introduction 
 Heart failure (HF) is a clinical syndrome caused by structural and/or functional cardiac 
abnormality, resulting in a reduced left ventricular function, and/or elevated intracardiac 
pressures.
1
 The prevalence of HF is approximately 1 – 2% of the adult population, rising to 
≥ 10% over 70 years of age.1–5 Today it is not possible to define a precise etiology of HF, 
but there are several factors involved in HF development, that go from ischemic heart 
disease to metabolic disorders, passing through genetic etiology.
1
 Focusing on metabolic 
disorders responsible of HF development, there is a wide spectrum of metabolic 
abnormalities that can lead to HF. 
  In the last years there was an increase of prevalence in many metabolic disorders, in 
particular in glucose metabolism abnormalities rate,
6
 in the context of westernized 
lifestyles, high-fat diets and decreased exercise, leading to increasing levels of obesity, 
insulin resistance (IR), compensatory hyperinsulinemia and ultimately, type 2 diabetes 
mellitus (T2DM).
6
 Although the most known cardiac (not ischemic) nosological entity 
related to glucose metabolism disorders is diabetic cardiomyopathy, IR, whether or not 
associated with T2DM, is a very frequent finding among HF patients, with a prevalence 
ranging from 33 to 70%.
7–9
 There is a bidirectional link between IR and HF, where 
although IR can predict HF, it often develops in HF patients, with more severe symptoms 
and worse clinical outcome.
10–13
 The degree of IR is significantly related with worsen 
clinical presentation and a poor prognosis in patients with HF, and it is known that 
metformin can prevent HF progression, improving exercise capacity.
7,10,12–14
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 The scope of this appraisal is to report the role of glucose metabolism abnormalities in 
the development of HF, defining a classification and diagnosis of glucose metabolism 
defects, which can lead to T2DM, and assessing pathophysiology and prognosis of HF 
related to glucose metabolism abnormalities.  
 
Classification of glucose metabolism abnormalities 
 Glucose metabolism disorders are a wide spectrum of abnormalities, characterized by 
elevated levels of blood glucose and impaired levels of circulating insulin. The actual 
classification of glucose metabolism abnormalities is based on recommendations from the 
World Health Organization (WHO) and the American Diabetes Association (ADA)
6,15–17
 
(table 1).  
 Beyond the classical four main etiological categories of DM (table 1) identified as 
type 1 DM (due to destruction of pancreatic beta-cells, progressing to absolute insulin 
deficiency. Although is typical of young age, it can occur at any age), T2DM 
(characterized by a combination of IR and beta-cells failure), gestational DM, and other 
specific types of DM (this entity includes single genetic mutation forms, DM secondary to 
other diseases, drug- or chemically induced DM, and infective forms), there is group of 
entities called “pre-diabetic disorders”, which are strictly related to cardiovascular (CV) 
events and in particular to HF development, and that includes a variety of disorders to be 
discussed.
6,17
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Different types of “pre-diabetic disorders” 
 All the types of glucose metabolism disorders (table 1), can often be considered as 
precursors of blown DM (generally T2DM), but in many cases are isolated and not related 
to the presence of T2DM. Between these entities, there are impaired fasting glucose (IFG) 
and impaired glucose tolerance (IGT), that are often referred to as “pre-diabetes”, 
reflecting the natural history of progression from normoglycaemia to T2DM.
6
 Considered 
the normal oscillation of fasting plasma glucose values day by day, many times these 
forms of glucose metabolism abnormalities could pass misdiagnosed. For this reason, IFG 
and IGT often can only be recognized by the results of an oral glucose tolerance test 
(OGTT).
6
 However, the most important form of glucose metabolism disorders, that, 
although could lead to T2DM, is common also in non-diabetic patients, and that is strongly 
related bi-directionally to HF, is IR. The concept of IR was proposed first time in 1936, 
and is generally defined as reduced biological action of insulin, such as inhibition of 
hepatic glucose production and insulin-mediated glucose disposal.
18–20
 There is a known 
correlation between obesity and IR development. In particular, patients with IR who are 
not obese by traditional weight criteria, may have an increased percentage of body fat 
distributed predominantly in the abdominal region.
17
 This type of glucose metabolism 
abnormality frequently goes undiagnosed for many years because in the beginning there is 
not a clear hyperglycemia, which develops gradually, without showing the classic 
symptoms of diabetes.
17
 Nevertheless, a great part of patients, experience CV events, 
including also the developing of HF, explaining the role of IR in HF pathogenesis also in  
40 
 
 
 
 
 
non-diabetic patients.
17
 As result of normal or elevated levels of insulin in patients with IR, 
the higher blood glucose levels cannot be compensated by high levels of circulating 
insulin, due to low effect of insulin. Thus, insulin secretion is defective in a first step in 
these patients and insufficient to compensate for IR. In a second step, considering the 
possible development of T2DM, also levels of circulating insulin become insufficient, 
needing a supplement of them.
17
 
 
Diagnosis of glucose metabolism abnormalities 
Diabetes mellitus, impaired fasting glucose and impaired glucose tolerance 
 As general rule, DM is defined by an elevated level of blood glucose. Based on this 
assumption, the WHO criteria for diagnosis of glucose metabolism abnormalities are based 
on fasting plasma glucose (FPG) and 2-hour post–load plasma glucose (2hPG) (when there 
isn’t an overt hyperglycemia (OGTT)) concentrations6,21 (table 2). On the other hand, in 
addition to these parameters of glucose metabolism disorders diagnosis, ADA recommend 
to use also glycated hemoglobin A1C (HbA1C). Therefore, for the diagnosis of DM, IFG 
and IGT there are several parameter to use, different between WHO and ADA. In 
particular, for WHO, the cut-points are the following:
6
 
1. Diabetes mellitus:  
- HbA1C can be used, with a cut-point ≥ 6,5%; 
- FPG is recommended, with a cut-point ≥ 126 mg/dL; 
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- 2hPG is recommended, with a cut-point ≥ 200 mg/dL; 
2. Impaired glucose tolerance: 
- FPG is recommended, with a cut-point < 126 mg/dL; 
- 2hPG is recommended, with a cut-point ≥ 140 - < 200 mg/dL; 
3. Impaired fasting glucose: 
- FPG is recommendend, with a cut-point of 110 – 125 mg/dL. 
Regarding ADA, the cut-points are the following:
6
 
1. Diabetes mellitus: 
- HbA1C is recommended, with a cut-point ≥ 6,5%; 
- FPG is recommended, with a cut-point ≥ 126 mg/dL; 
- 2hPG is recommended, with a cut-point ≥ 200 mg/dL; 
2. Impaired glucose tolerance: 
- FPG is recommended, with a cut-point < 126 mg/dL; 
3. Impaired fasting glucose: 
- FPG is recommendend, with a cut-point of 110 – 125 mg/dL. 
Insulin resistance 
Regarding IR, the homeostasis model assessment (HOMA) index has proved to be 
a robust and reliable tool for the assessment of IR (table 2). This method is based on a 
homeostatic mathematic model considering FPG and fasting plasma insulin. Several 
studies
18,20,22–28
 have assessed a normal range value for HOMA-index that is considered 
now between 0,23 and 2,5.  
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Strategy for early detection of impaired glucose metabolism 
As known, DM does not cause specific symptoms for many years, which could 
explain the great number of T2DM undiagnosed over several years. Overall, this could be 
the reason of several CV disorders DM related which occur before the diagnosis of DM. 
On the other hand, as known, IR (a frequent precursor of T2DM) is always asymptomatic 
and is not associated with hyperglycemia, for this reason, it is more difficult to detect with 
routinely exams IR
6
. However, screening of hyperglycemia (or of IR), should be targeted 
to high-risk individuals of CV disease and HF.
6
 So, according to current guidelines
6
, the 
approaches for early detection of glucose metabolism abnormalities are: 
- Measuring PG or HbA1C; 
- Using demographic and clinical characteristics to determine the likelihood of impaired 
glucose metabolism (for the eventual evaluation of HOMA-index); 
- Evaluate the presence of possible risk factors of glucose metabolism disorders, CV events 
and HF (for the eventual evaluation of HOMA-index). 
 
Pathophysiological insights of heart failure related to glucose metabolism disorders 
 As previously described, IR is a direct precursor of T2DM, and the consequent 
compensatory hyperinsulinemia peculiar of IR, with consequent elevated levels of PG, 
associated with clustering of CV risk, can lead to several CV disease.
6
 As known, T2DM 
patients are generally obese (or with higher levels of fat abdominally distributed), and the 
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release of free fatty acid (FFA) from adipose tissue, directly impairs insulin sensitivity
6,29
 
(figure 1). So the “primum movens” is IR, with several consequent mechanism involved in 
HF presentation and progression. However, well known is the bidirectional link between 
IR and HF,
11
 where several studies indicate that DM and IR are not only causative factors 
of HF,
30–32
 but patients with HF and DM or IR showed a more aggressive form of left 
ventricular (LV) dysfunction, with a higher mortality rate.
33
 Insulin resistance is the entity 
with higher prevalence in HF patients (up to 60%),
34
 with a complex pathophysiological 
interaction between these two conditions, since IR may be the cause and consequence of 
HF at the same time.
30
 Similarly, DM has a prevalence of 10 – 40% in patients with HF,35 
showing a quite high prevalence, but lower than IR. This could explain the more important 
and potential role of IR in HF development (and vice versa), compared to DM, that was 
widely discussed in the years.
8,9,30
     
Pathophysiology of heart failure in IR and DM  
 Well known is the role of IR and DM in several functional, metabolic and structural 
alterations that involve myocardial tissue and that can lead to HF (figure 1). In the initial 
stage of HF, there is a change in substrate utilization, where glucose becomes the primary 
substrate oxidized.
9
 Hyperglycemia is responsible for several cellular pathway 
abnormalities, going from increased polyol, modification of proteins, and formation of 
advanced glycation endoproducts, to increased protein kinase C expression, phenomenon 
leading to overproduction of superoxide and consequent oxidative stress
30,36
 (figure 1). On 
the other hand, the increase of FFA myocardial uptake, typical of diabetes and obesity, 
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leads to long-chain FFA oxidation and to a disproportionate oxidative request to 
mitochondria with uncoupling of mitochondrial oxidative phosphorylation
30,37
 (figure 1). 
In addition, the impaired expression of contractile proteins, is responsible for depressed 
myofibrillar ATP activities and abnormalities of the sarcoplasmic reticular and 
sarcolemmal calcium transport process, with consequent calcium overload and impaired 
diastolic function.
30,38
  
Hyperactivation of adrenergic system  
 Another consideration to do is on the impairment of cardiac sympathetic innervation, 
commonly observed in HF patients affected by DM and/or IR. Paolillo et al,
34
 in a recent 
study, showed in HF patients with DM, or without DM, but with IR, a more impaired 
cardiac sympathetic innervation, compared with non-diabetic and non-IR patients, 
indicating a chronic adrenergic hyperactivity, that correlates with high levels of 
hyperglycemia and HF development and worsening. In the same year, Rengo et al,
39
 
reported that levels of GRK2, a protein kinase involved in the desensitization of cardiac 
beta-receptors, are significantly more elevated in HF patients with DM compared with 
non-diabetic patients with HF, meaning a stronger adrenergic activation, known to be 
involved in progression and worsening of HF. This is a peculiarity of DM and IR patients 
with HF, where it is well known that because of adrenergic overactivity, HF is complicated 
by DM and IR.
8
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Epidemiology of heart failure in glucose metabolism abnormalities and vice versa 
 Since now, it was widely discussed the bidirectional link between HF and glucose 
metabolism disorders. Well known is the prevalence of HF in the general population, that 
is about 1 – 2%,1–5 rising to 12 – 30% in diabetic patients.40,41 Glucose metabolism 
abnormalities (in particular DM and IR) are independent risk factors for the development 
of HF. In the Framingham study, the relative risk of HF in patients with T2DM was 
doubled for men and six times as high in women
6,42
. These data were confirmed by the 
National Health and Nutrition Examination Survey, where T2DM was showed to be an 
independent predictor of HF (HR 1.85, 95% CI 1.51 – 2.28).43  
 On the other hand, the prevalence of DM in the general population is about 6 – 8 %,6 
but as described by MacDonald et al,
44
 rises to 12 – 30% in HF patients. However, HF 
patients are older than general population. This could be considered a bias selection, 
although is widely known (also in the general population) not only the role of glucose 
metabolism disorders in development of HF, but also the major prevalence of glucose 
metabolism abnormalities (in particular DM and IR, as previously described) in HF 
patients. Confirming these data, the TOSCA registry,
7
 a recent Italian registry, made on 
526 patients (81% male, age 62.5 ± 12.2 years) has shown a prevalence of IR in HF 
patients of 30 – 35%, in line with previous studies, demonstrating the great impact of 
glucose metabolism abnormalities on HF. 
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Prognosis of heart failure related to glucose metabolism abnormalities 
Great trials 
 Today, HF can be considered the major cause of hospitalization in patients with 
glucose metabolism abnormalities. These data were confirmed by the Hypertension, 
Microalbuminuria or Proteinuria, Cardiovascular Events and Ramipril (DIABHYCAR) 
trial,
45
 with a mortality 12-fold higher in patients with HF and glucose metabolism 
disorders, compared to patients without HF (36% vs 3%). On the other hand, in the BEta 
blocker STroke (BEST) trial, impaired glucose metabolism increased the risk of 
hospitalization in HF patients, with T2DM as independent predictor of mortality, mostly 
for HF.
46
 More recently, the Metoprolol CR/XL Randomized Intervention Trial in 
Congestive Heart Failure (MERIT-HF),
47
 showed HF patients with glucose metabolism 
alterations, to be more hospitalized than patients free from DM.  
Previous studies 
 A previous study of Suskin et al,
12
 studied 663 patients with abnormalities in glucose 
metabolism (DM or IR) and HF, assessing prognostic role of glucose metabolism, in 
particular, evaluating functional class, six minute walking performance and LV function. 
In this cohort of patients, they found a greater proportion of diabetic patients compared to 
non-diabetic patients in NYHA class III/IV (161 vs 77, p = 0.011), with a higher value of 
insulin in non-diabetic patients in NYHA class III/IV compared to NYHA class I/II (19.6 ± 
2.3 vs 10.2 ± 0.6 mU, p < 0.005). In addition, among non-diabetic patients, significantly 
more NYHA class III/IV patients had elevated HOMA-index levels (44% vs 28%, p < 
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0.005) compared to NYHA class I/II patients. These data were confirmed also for six 
minute walking distance, that was significantly shorter in diabetic patients compared to 
non-diabetic patients (369 ± 7 vs 385 ± 4 meters, p = 0.03). Furthermore, patients with 
impaired HOMA-index had a significantly shorter six minute walking distance than those 
with normal values (372 ± 7 vs 391 ± 5 meters, p = 0.02).  
 A more recent study of Doehner et al,
13
 evaluated insulin sensitivity in 105 male 
patients with HF. After a mean follow up of 44 ± 4 months, patients with an insulin 
sensitivity below the median value had a worse survival  (61% at two years) compared to 
patients with an insulin sensitivity above the median value (83% at two years) (RR 0.38, 
95% CI 0.21 – 0.67, p = 0.001). Furthermore, insulin sensitivity resulted independent 
predictor of mortality in the study cohort. 
Therapeutic possibilities 
 Considering the impact on prognosis of glucose metabolism abnormalities, it is 
possible affirm that DM and IR can be considered as potential target of HF. Although is 
known the role of several new pharmacological agents in the reduction of mortality in HF 
diabetic patients,
48
 poor is known about the potential treatment of IR and its impact on HF 
prognosis. Considering this assumption, Wong et al,
14
 randomized in a double-blind, 
placebo-controlled study 62 non-diabetic HF patients, to receive either four months of 
metformin or matching placebo. Compared with placebo, metformin decreased HOMA-
index, improving also the secondary endpoint of the slope of the ratio of minute ventilation 
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to carbon dioxide production (VE/VCO2 slope). These data confirm the hypothesis that 
treatment of IR should be protective in patients with HF. 
 
Summary 
 There is a strong correlation between glucose metabolism abnormalities and HF, with 
a bidirectional link between them, where glucose metabolism abnormalities at every step 
can affect HF. On the other hand, DM and IR are more prevalent in HF patients, and 
patients with both HF and DM have a worst prognosis, due to a combination of effects of 
both the components. Well known is the role of some new drugs in reducing the mortality 
in HF patients with DM, but more studies are warranted to know the real effect of 
treatment of IR in patients with HF. 
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Tables 
 
Table 1. Different types of glucose metabolism disorders 
CLASSIFICATION OF GLUCOSE METABOLISM 
ABNORMALITIES 
Type 1 diabetes mellitus 
Type 2 diabetes mellitus 
Other specific types of diabetes mellitus 
          Genetic mutation forms 
          Secondary to other diseases           
                    Diseases of the exocrine pancreas 
                    Endocrinopathies 
          Drug or chemically induced 
          Infective forms 
Gestational diabetes mellitus 
Pre-diabetic disorders 
Impaired fasting glucose 
Impaired glucose tolerance 
Insulin resistance 
     
 
Table 2. Diagnostic evaluation of glucose metabolism disorders (according to WHO and 
ADA) 
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Diabetes mellitus 
          Glycated hemoglobin A1C (HbA1C) 
          Fasting plasma glucose 
          2-hour post–load plasma glucose (OGTT) 
Impaired glucose tolerance 
          Fasting plasma glucose 
          2-hour post–load plasma glucose (OGTT) 
Impaired fasting glucose 
          Fasting plasma glucose 
Insuline resistance 
          Homeostasis model assessment (HOMA) index 
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Figures 
 
 
Figure 1. Pathophysiology of HF development related to insulin resistance.  
FFA = free fatty acid; HF = heart failure. 
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Abstract 
BACKGROUND: Life expectancy of HIV patients has increased considerably as a result 
of antiretroviral therapy, and cardiovascular (CV) disease has emerged as an important late 
concern. HIV infection may affect systolic function either in adults or children, however 
data on diastolic function and markers of CV risk, such as epicardial adipose tissue (EAT) 
and intima-media thickness (IMT), are lacking. Aim of the present study is to evaluate left 
ventricular function, EAT and IMT in children and young adults with vertically-acquired 
HIV infection.  
METHODS and RESULTS: We enrolled 29 subjects on antiretroviral therapy (ART) (13, 
45% male; median age of 14.0 and IQR 8.7), and 29 age-matched controls. All patients and 
controls underwent echocardiographic evaluation, with study of the systo-diastolic function 
and measurement of the EAT, and a carotid ultrasound study for IMT measurement. 
Comparing HIV-infected patients to healthy controls, we found a statistical significant 
increase of EAT and IMT (EAT: 3,16 ± 1,05 vs 1,24 ± 0,61 mm; p < 0,0001. IMT: 0,77 ± 
0,15 vs 0,51 ± 0,11 mm; p < 0,0001), and a significant reduction of ejection fraction, 
evaluated with biplane Simpson method (52,3 ± 17,49% vs 66 ± 4,24%; p = 0,029). These 
results are not related with age, gender, degree of lipodystrophy, dyslipidemia, 
hyperinsulinism and ART duration or the use of single antiretroviral classes. 
CONCLUSIONS: Vertically-infected HIV children and young adults show an increased 
thickness of the EAT and IMT, expression of potentially increased CV risk. They also 
show an impaired systolic function.  
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Introduction 
 Human immunodeficiency virus (HIV) infection is a major cause of morbidity and 
mortality worldwide. In developed countries, where life expectancy has increased 
considerably as a result of antiretroviral therapy (ART), cardiovascular diseases (CVD) 
have emerged as an important late comorbidity in HIV patients [1,2]. 
Results from the Pediatric Pulmonary and Cardiovascular Complications of Vertically 
Transmitted HIV Infection (P2C2 HIV) study have shown that subclinical cardiac 
abnormalities develop early in HIV1-infected children, and that cardiac alterations are 
frequent, persistent, and often progressive [3-6]. Common abnormalities include dilated 
cardiomyopathy (decreased left ventricular [LV] contractility and LV dilation) and 
inappropriate LV hypertrophy (high LV mass with decreased height and weight) [3]. 
 Echocardiographic abnormalities can be found in up to 44% of patients infected with 
HIV [7]. These findings include pericardial effusion, LV dysfunction, dilated 
cardiomyopathy, infective endocarditis, pulmonary arterial hypertension, and cardiac 
masses such as lymphoma and Kaposi’s sarcoma of the heart. In addition, ART has been 
associated with the development of ischemic heart disease and LV diastolic abnormalities 
[8].  
 Although most data come from adult populations, evidence is also available for an 
association between HIV infection and systolic and diastolic dysfunction in children 
[9,10], and it has been demonstrated that children undergoing ART show decreased 
incidence of CVD [11,12].  
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 In recent years new markers of increased CV risk have emerged. Epicardial adipose 
tissue (EAT), that has the same embryogenic origin of the visceral fat [13], has been 
reported to be associated with CV risk and metabolic syndrome [14,15]. Increased EAT 
thickness in HIV-infected adults compared to healthy controls has been reported [16,17], 
with an association between EAT and lipodystrophy [18]. However, data on children and 
young adults with vertically acquired HIV infection are lacking. 
Similarly, the increase in intima-media thickness (IMT) is associated with higher CV risk, 
and a higher IMT has been reported in HIV-infected children, compared to non-infected 
patients [19]. The IMT thickness appears higher in naïve children than in HIV-patients 
undergoing ART therapy [20]. 
 The aim of this study was to assess EAT, IMT and left ventricle function in young 
patients with vertically-acquired HIV infection, to correlate these parameters to metabolic 
profile and anti-retroviral treatment.  
 
Methods 
This cohort study was carried out between January 1
st
, and November 30
th
 2017 at the  
Regional Reference Center for Pediatric HIV/AIDS of the University of Naples Federico 
II. The Referral Center covers a territory of about 5 million inhabitants in the most 
populous region of the Southern Italy, and manages about 30 HIV-infected children and 
adolescents with 1-2 new diagnosis/year of HIV infection in the last years.  
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All patients currently in follow-up were enrolled in the study, and a group of age-matched 
subjects was enrolled as controls. The study was conducted according to the principles of 
the Helsinki declaration and the study protocol was approved by the Ethical Committee of 
the University Federico II of Naples (protocol number 153/16). All patients and caregivers, 
according to age, signed an informed consent after receiving specific information from the 
study coordinators.  
 
Anamnestic evaluation 
 All patients underwent anamnestic and lifestyle evaluation (physical activity, smoking, 
drinking, drug addiction, eating habits), clinical and viro-immunological assessment with 
measurement of HIV viral load and CD4
+
 count. In addition, current ART, history of ART 
regimens and duration of single antiretroviral classes were reviewed. 
 
Evaluation of the metabolic and CV risk 
 All patients underwent clinostatic and orthostatic blood pressure measurement, 
followed by the evaluation on blood sample of lipid profile (total cholesterol, high density 
lipoprotein (HDL), low density lipoprotein (LDL), triglycerides) and glucose  
profile (fasting glucose, basal insulin, homeostatic model assessment (HOMA) index). We 
also evaluated the presence of metabolic syndrome, considering the International Diabetes 
Federation (IDF) diagnostic criteria and the modified National Cholesterol Education 
Program Adult Treatment Panel III (NCEP-ATP III) criteria [21]. Lipodystrophy was 
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classified as absent, mild (mild lipodystrophy of face and arms) and severe (severe 
lipodystrophy of face and arms, with involvement of abdomen and legs). 
 
Echocardiography and carotid assessment 
 For all echocardiographic measurements, the final values were obtained after 
averaging over two cardiac cycles. The evaluation of LV ejection fraction was made with 
Simpson biplane mode, tracing tele diastolic and tele systolic volume both in four and two 
chamber apical view (n.v. 52-70%). 
 The evaluation of LV diastolic function was made evaluating the E/A ratio and the 
E/E’ ratio. The E/A ratio was evaluated in a four chambers apical view, using pulsed 
Doppler, applied on the coaptation point of the mitral flaps. The E wave is the early 
component of the left ventricle diastolic filling, meanwhile the A wave corresponds to the 
atrial systole. The E/A ratio was considered normal for a value higher than 1. Values lower 
than 1 (first type of diastolic dysfunction) or higher than 2 (third or fourth type of diastolic 
dysfunction) were considered abnormal. The E’ wave was obtained applying a tissue 
Doppler on the mitral annulus (medial and lateral). A E’ mean value lower than 8 indicate 
a diastolic dysfunction, but, considering the E/E’ ratio, the normal value is lower  
than 8. A value between 8 and 13 can be considered as first type of diastolic dysfunction, 
meanwhile a value higher than 13 can be considered as a third or fourth type of diastolic 
dysfunction.  
 The EAT was measured in a parasternal long-axis view, on the top of the right 
ventricle free wall, considering the maximum thickness, as end-systolic measurement 
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(Figure 1). In the evaluation of the CV profile we also included a carotid ultrasonography, 
with a Doppler linear probe, for the evaluation of the IMT. Specifically, IMT was 
measured at common carotid level 1 cm before carotid bifurcation in both right and left 
carotid arteries, using an average all the 2 measurements. All measurements were 
performed by FM. Inter-observer variability for EAT, LV ejection fraction and IMT were 
calculated in 10 randomly selected exams. A second observer (CDA), who was blinded to 
the initial analysis, repeated all measurements for quantification of inter-observer 
variability. 
 
Statistical analysis  
Data were collected in a Microsoft Excel database and statistical analysis were 
performed by using IBM SPSS Statistics v25.0. Categorical variables were reported as 
percentages. Continuous variables were reported as mean ± standard deviation (SD), and 
variables with skewed distributions were presented as median and interquartile range 
(IQR). Normal distribution was assessed by 
Kolmogorov- Smirnov test. Student t test for paired samples was used to compare mean  
for baseline characteristics and bio humoral parameters between patients and controls. 
Student t test for unpaired data was used to compare differences in LV systolic function, 
LV diastolic function, EAT and IMT between HIV-infected patients and controls. 
Correlation between cardiovascular risk factors and type of therapy with EAT levels and 
IMT was assessed by Pearson's (or Spearman's) correlation and univariate regression. 
Multiple linear regression analysis was used to adjust for potential confounders. Inter-
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observer variability was evaluated by calculating the interclass correlation coefficient, with 
a cut-off value > 0.75 as indication of good agreement, as proposed by Burdock et al [22]. 
Statistical significance has been accepted at p < 0.05. 
 
Results 
Study population 
We enrolled 29 consecutive HIV-infected patients on ART (13, 45% male; median age 
of 14.0 and IQR 8.7 (baseline characteristics reported in Table 1), and 29 age-matched 
healthy controls, without differences for demographic, lifestyle and metabolic 
characteristics with patients (Table 1). According to the CDC classification of HIV-
infected children and adolescents [23], most patients were in class 3 (21, 72%), 3 patients 
in class 2 (10%) and 5 patients in class 1 (17%). 
The majority of patients (72%) had undetectable viral load defined as HIV RNA < 40 
copies/ml and the mean CD4
+
 count value was 1032 cells/μL at enrollment (Table 1). At 
the time of enrollment, all patients were on anti-retroviral treatment with nucleoside  
reverse transcriptase inhibitors backbone in association with a protease inhibitor in 23 
(79%) patients (15 patients on lopinavir/ritonavir, 8 patients on darunavir/ritonavir) or an 
integrase strand transfer inhibitor in 6 (21%) patients (5 dolutegravir and 1 raltegravir). 
The median duration of overall ART in the study population was 120 months (IQR 156); 
specifically, patients were treated with at least one nucleoside reverse transcriptase 
inhibitors for 98 months (IQR 130.5), with protease inhibitors for 96 months (IQR 130.8), 
with non-nucleoside reverse transcriptase inhibitors for a median of 18 months (IQR 23) 
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and with an integrase strand transfer inhibitor for a median of 15.5 months (IQR 23.5). 
None of patients in our cohort had hypertension (mean SBP 115 ± 12, and DBP 68 ± 8 
mmHg) or diabetes (mean fasting glucose value 72 ± 15 mg/dl), but 6 patients (21%) 
showed an HOMA-index > 2,5, indicating an insulin-resistance state. Dyslipidemia was 
found only in 2 (7%) patients, with a mean value of LDL cholesterol of 95 ± 26 mg/dl. 
Only 2 patients had an altered body mass index (mean value 20 ± 4 kg/m
2
), and 1 patient 
met ICD or NCEP-ATP III criteria for metabolic syndrome (Table 1). 
A variable degree of lipodystrophy was reported in about a third of patients (Table 1). 
 
Cardiovascular evaluation 
Compared with healthy controls, HIV-infected children showed a statistical significant 
increase in EAT (3,16 ± 1,05 vs 1,24 ± 0,61 mm; p < 0,0001, Figure 2A) and IMT (0,77 ± 
0,15 vs 0,51 ± 0,11 mm; p < 0,0001, Figure 2B). Although absolute values of left 
ventricular ejection fraction were within the normal values in both populations, the mean  
left ventricular ejection fraction was significantly reduced in HIV-infected patients in 
comparison to healthy control subjects (58,5 ± 6,66 vs 66 ± 4,24 %; p = 0,029) (Figure 
2C). We didn’t find statistical significant differences between patients and controls 
regarding diastolic function. 
Patients’ age and gender, HIV class and level of CD4, the duration of ART (including 
each antiretroviral drug class), the use of first generation protease inhibitors, the use of 
specific antiretroviral drug class, the presence or degree of lipodystrophy, the presence of 
93 
 
 
 
 
 
dyslipidemia, the degree of insulin resistance were investigated as possible factors 
affecting the increase of EAT and/or IMT, however for none of them a statistical 
significant correlation was demonstrated. Children with HOMA index >2.5 seemed to have 
a trend toward increase in EAT, showing higher value (3.25 ± 0.87) than children with 
HOMA<2.5 (2.92 ± 0.85), but this difference was not statistically significant (p=0.34). 
Similarly, children with HOMA > 2.5 had slightly higher values of IMT (0.76 ± 0.16 vs 
0.64 ± 0.31), although this difference did not reach statistical significance (p=0.27). 
The interclass correlation coefficient for inter-observer variability for LV ejection 
fraction, EAT and IMT were 0.925, 0.987 and 0.960 respectively. 
 
Discussion 
Cardiac dysfunction has been previously reported in adults and children with HIV  
infection, although it’s not completely clear whether those alterations are directly related to 
HIV or to antiretroviral treatment. We confirmed a decrease of the absolute value of 
ejection fraction and increased values of IMT in a population of children and adolescents 
with vertically-acquired HIV infection. Moreover, this is the first study documenting a 
significant increase of EAT in children and adolescents with HIV infection. Systolic 
function reduction is consistent with previous studies, that also documented a reduction in 
ejection fraction in subjects with HIV infection. Lipshultz et al [9], showed in a cohort of 
93 HIV children, a reduction of LV fractional shortening after 8 months of follow-up, 
compared with healthy control subjects. More recently, the same group [10], confirmed 
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these data showing a reduction in cardiac function in HIV children with higher current 
viral load. The CHAART-2 study [24] showed the effectiveness of ART in improving LV 
fractional shortening and LV contractility by comparing a cohort of 74 HIV children on 
ART with 140 HIV-infected controls unexposed to ART. In particular, they found a 
significant difference (expressed as Z-score of normal values) in LV fractional shortening 
(0.26 vs -1.19 respectively, p = 0.02) and LV contractility (0.09 vs -0.88, p = 0.002), 
between cases and controls respectively. According with our data, LV function appeared 
different from controls but not significantly impaired, however, they also reported a 
relevant impact of ART on LV function, not confirmed in our study.  
In addition, as previously reported in other cohort of HIV-infected children and adults, 
we showed an increase of IMT in our population. Although other studies, even in large 
population, confirmed this finding in HIV-infected patient aged below 30 years [25], the  
clinical relevance and the correlation of this finding with HIV state of infection and ART 
are still matter for discussion. Charakida et al [19] reported a significant greater IMT in 
HIV infected children than in healthy control subjects, and demonstrated a potential role of 
ART, showing higher IMT in those patients who received protease inhibitors. In contrast, 
Idris et al [20] found higher IMT values in naïve children with vertically acquired HIV 
infection compared to those on ART and healthy children.  
In the last two years, other studies confirmed an increase in the IMT in HIV-infected adults 
[26] and children or adolescents [27] patients. In contrast with our results, Augustemak de 
Lima et al also reported alteration in CV profile and a possible role of ART on IMT in 
underage patients [27]. 
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This is the first study investigating the EAT in HIV-affected children and adolescents. 
Currently, there are only few studies that evaluated EAT in HIV adult patients, showing an 
increase of epicardial fat in these patients. Zona et al [28], in a cohort of 240 HIV adult 
patients, showed an increase of EAT, more evident in men than in women. Differently 
from our study, they found a correlation between the higher EAT and CD4
+
 levels. Other 
studies correlated EAT to body-weight in HIV patients [16], showing a correlation 
between EAT and metabolic syndrome. Guaraldi et al [18] found an increased EAT that 
correlated with metabolic syndrome in 876 adult patients and a correlation between EAT 
and lipodystrophy. Finally, more recently, another study of Brener et al [17], studied 579 
HIV-infected adult patients and 353 controls, showing a thicker EAT in  
HIV patients treated with ART. However, differently from our study, Brener et al [17] 
found a greater EAT in patients with greater BMI, in hypertensive patients, in diabetic 
patients and in dyslipidemic patients, suggesting a potential contribution of CV risk factors 
on EAT. In our study, there were no correlation between CV risk factors and increased 
EAT or IMT. Moreover, we didn’t find any correlation between HIV class and level of 
CD4, the duration of ART, the use of old generation protease inhibitors, the use of any 
different antiretroviral drug class, the presence and degree of lipodystrophy therapy and 
EAT or IMT. These results suggest a potential role of the disease defining an increased CV 
risk in these patients.    
Limitations 
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 The relatively small number of patients is a limitation of this study, although the 
cohort of patients includes all subject currently seen at the reference center and the 
matching with controls may ensure a statistical reproducibility of results. Lack of follow up 
makes the current findings hypothesis generating and warranting further evaluation.  
Conclusions 
The findings of the present study demonstrated that in patients with HIV treated with 
ART, systolic function is reduced and IMT and EAT are increased compared to healthy 
control. Taken together these findings suggest subclinical cardiovascular damage in HIV 
patients despite the absence of conventional CV risk factors. 
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Table 
General characteristics Patients (n = 
29) 
Controls (n = 
29) 
p 
value 
Male (N, %) 13 (45) 13 (45)  
Age at enrollment (median, IQR) 14.0 (8.7) 13.6 (8.2) 0.932 
Age at diagnosis (median, IQR) 1 (6) NA  
Smokers (N, %) 7 (24.1) 5 (17.2) 0.265 
Regular alcohol consumer (N, %) 1 (3.4) 0 (0)  
Drug consumer (N, %) 0 (0) 0 (0)  
Viro-immunological characteristics    
Patients in class 1 (N, %) 5 (17.2) NA  
Patients in class 2 (N, %) 3 (10.4) NA  
Patients in class 3 (N, %) 21 (72.4) NA  
Patients with undetectable HIV load 
(N, %) 
21 (72.4) NA  
HIV viral load (mean ± SD) 6176 ± 11686 NA  
CD4
+
 cell count (mean ± SD) 1032 ± 875 NA  
Percentage of CD4
+
 (mean ± SD) 33.9 ± 10.6 NA  
Duration of ART (median, IQR) 120 (156) NA  
Duration of PI treatment (median, 
IQR) 
96 (130) NA  
Duration of NRTI treatment (median, 
IQR) 
98 (130) NA  
Duration of NNRTI treatment 
(median, IQR) 
18 (23) NA  
Duration of II treatment (median, 
IQR) 
15.5 (23.5) NA  
Metabolic and cardiovascular 
parameters 
   
BMI (mean ± SD) 20 ± 4 19 ± 6 0.153 
BMI < 5 percentile (n, %) 3 NA  
BMI 5-25 percentile (n, %) 11 NA  
BMI 26-75 percentile (n, %) 8 NA  
BMI 76-95 percentile (n, %) 2 NA  
BMI > 95 percentile (n, %) 3 NA  
Total cholesterol in mg/dl (mean ± 
SD) 
157 ± 36 156 ± 46 0.959 
HDL cholesterol in mg/dl (mean ± 
SD) 
42 ± 12 54 ± 21 0.063 
LDL cholesterol in mg/dl (mean ± 
SD) 
95 ± 26 101 ± 29 0.407 
Triglycerides in mg/dl (mean ± SD) 124 ± 50 101 ± 65 0.058 
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Metabolic Syndrome (N, %) 1 (3)  1 (3)  
No lipodystrophy (N, %) 21 (72.4) NA  
Mild lipodystrophy (N, %) 5 (17.2) NA  
Severe lipodystrophy (N, %) 3 (10.4) NA  
Fasting glucose in mg/dl (mean ± SD) 72 ± 15 82 ± 28 0.151 
HOMA index (mean ± SD) 1,9 ± 3,9 NA  
Systolic blood pressure (mean ± SD) 115 ± 12 117 ± 16 0.639 
Diastolic blood pressure (mean ± SD) 68 ± 8 65 ± 11 0.725 
 
Table 1. Patients baseline characteristics 
IQR: interquartile range; SD: standard deviation; HOMA: homeostasis model assessment.  
 
 
Figures 
 
 
Figure 1. Echocardiographic assessment of epicardial adipose tissue. The left side is an 
end-systolic image, where EAT is more represented. The right side is an end-diastolic 
image, with the minimum thickness of EAT. 
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Figure 2. Difference of EAT, IMT and left ventricular ejection fraction between patients 
and controls 
A: difference of EAT between patients and controls. B: difference of IMT between patients 
and controls. C: difference of left ventricular ejection fraction between patients and 
controls. 
EAT: epicardial adipose tissue. IMT: intima-media thickness. 
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Congenital heart disease: from childhood to adulthood 
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CHAPTER 8. 
Hypertrophic cardiomyopathy in mitochondrial disorders: description of an 
uncommon clinical case 
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Abstract 
Background: Pulmonary hypertension (PH) is a progressive disease with high mortality 
rate. Although is known the role of imaging RV size and function in predicting prognosis, 
it is unknown the role of the interval changes of these parameters on prognosis. 
Purpose: The aim of this study is to evaluate the impact of CMR and echocardiographic 
parameters of RV size and function on prognosis in patients with PH, at baseline and 
during follow-up, considering also the comparison of echocardiographic parameters of 
circumferential RV function with CMR-derived RV function. 
Methods: PH patients with both CMR and TTE exams within 1 month were followed over 
a mean period of 57±24 months. In 20 of these patients, after 47±16 months, a second 
CMR and echocardiographic exam were performed. As primary endpoint, a composite of 
death for any cause, hospitalization for worsening of PH, start with i.v. prostanoid therapy, 
long term oxygen therapy, atrial septostomy or lung transplantation was defined. The 
secondary endpoint was defined as disease progression, i.e. a composite endpoint including 
a reduction in 6 minute walking test distance of more than 15%, accompanied by 
worsening in NYHA class or escalation of pulmonary vasodilator therapy, or increase in 
NT-Pro-BNP value by more than 50%.  
Results: Thirty-six patients (15 females/21 males), mean age 44±16 years were included in 
the study. The primary endpoint was reached by 14 patients, while progression of the 
disease was present in 30 patients. None of the baseline parameters was predictive of 
outcome, nor of disease progression. In the 20 patients with follow-up exams, an interval 
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increase in RV volumes assessed by CMR was highly predictive of an adverse outcome, 
with a more likely adverse event during the subsequent follow-up period of 14±12 months 
after the second imaging exam. None of the echocardiographic interval changes were 
predictive of outcome. A correlation of FAC with CMR-derived RV-EF (r = 0.469, p = 
0.003) was found. 
Conclusion: An increase in RV end-diastolic volumes on CMR is associated with a worse 
outcome. A weak correlation of fractional area change with CMR-derived RV function 
was found. 
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Introduction 
Pulmonary arterial hypertension (PAH) is a progressive vascular disease leading to 
right ventricular failure. Despite the advent of disease targeted therapies, contemporary 
registries still observe mortality rates of 20-30% at 3 years and prognostication remains an 
important aspect in the management of PAH patients (1, 2). A first equitation to estimate 
survival at the time of diagnosis was proposed in 1991 based on the National Institute of 
Health registry data. Prognosis in PAH was derived from hemodynamic measurements, 
incorporating right atrial pressure, mean pulmonary artery pressure and cardiac index (3). 
In a more contemporary equitation and in the current practice guidelines, hemodynamic 
measures are complemented by clinical variables related to exercise capacity (e.g. 6 
minutes walking distance, peak oxygen consumption, functional class), gender, PAH 
subgroup, neurohumoral activation and imaging parameters (e.g. the presence of 
pericardial effusion and right atrial size) in order to further improve prognostication (2, 4).  
As the clinical outcome in PAH depends on ability of the right ventricle to cope 
with the increased vascular load, imaging studies assessing right ventricular (RV) function 
may be particularly helpful in refining PH prognosis. Transthoracic echocardiography 
provides an easily available non-invasive tool to monitor pulmonary arterial pressure and 
RV size and function (5). Several echocardiographic indices of RV function have been 
evaluated for prognostication in PH, such as the amount of systolic tricuspid annular 
motion (TAM), its systolic velocity on tissue Doppler imaging, the RV endsystolic 
remodeling index (RVESRI), the fractional area change (FAC) of the right ventricle or its  
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global strain (6-11). Recently, cardiac magnetic resonance imaging (CMR) has emerged as 
reference method for quantifying RV volumes, ejection fraction, mass and pulmonary flow 
(12). CMR-derived stroke volume as well as right and left ventricular volumes at baseline 
were also shown to be predictive of PAH prognosis (13), and interval changes in RV 
ejection fraction (EF) were superior to measuring pulmonary vascular resistance in 
predicting outcome (14). 
So far, no head-to-head comparison of the prognostic ability of both imaging 
techniques in unselected PAH patients has been reported. Transthoracic echocardiography 
is widely available, inexpensive and safe, but has limitations in terms of obtaining 
adequate images and accurate measurement of RV volumes. CMR provides high-
resolution three-dimensional images and avoids any geometrical assumptions to quantify 
RV volumes and function. However, it is expensive, time-consuming, and requires specific 
technical and analytical expertise. CMR is contraindicated in certain patients with 
electronic devices and breath holding may be challenging (15). All in all, both imaging 
techniques have their advantages and drawbacks.  
In the present pilot study, we aimed to compare the prognostic accuracy of standard 
echocardiographic surrogates of RV function with CMR-derived RV EF and volumes. In a 
second step, we analyzed the predictive value of baseline measures versus interval 
changes. We hypothesized that CMR-derived RV EF is superior to echocardiographic 
measures of RV function in predicting outcome and that interval changes are more 
predictive of outcome than baseline measures.  
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Methods 
Study patients 
 We evaluated 36 patients with pulmonary hypertension of different etiologies. All 
patients underwent a CMR exam and a transthoracic echocardiogram within 1 month. In 20 
patients, a second CMR and echocardiographic exam were performed after 47 ± 16 months 
(range 24-75 months) of follow-up. After the second CMR exam, these 20 patients were 
under clinical follow-up for another 14 ± 12 months. We routinely scan all patients with 
pathologies affecting the right ventricle (i.e. with congenital cardiac defects, RV dysplasia 
or pulmonary hypertension) with CMR in a 3 - 5 years interval or earlier if clinically 
necessary. In all patients, NYHA functional class, resting oxygen saturation, 6-MWD, 
serum NT-proBNP and concomitant medication at the time of the first and second CMR 
exam were documented.  
Transthoracic echocardiography 
Transthoracic Doppler echocardiography was performed using an Acuson Sequoia 
C 512 (Acuson Corporation, Siemens, Mountain View, CA, USA) or Philips IE 33 
ultrasound systems (Philips, Amsterdam, The Netherlands) with a 3.5 MHz transducer 
including second harmonic imaging. All echocardiography images and clips were stored 
off-line (Argus version 4.01, Syngo MR B13, Siemens Medical Solutions, Erlangen, 
Germany). Values were obtained after averaging over two cardiac cycles. Patients were 
examined in supine left lateral position.  
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The following surrogates of right ventricular function were obtained in the RV four 
chamber view: 1) TAM: defined as the distance between the basal end-diastolic to systolic 
motion of the tricuspid annulus measured on M-mode pictures of the tricuspid lateral 
annulus (16); 2) FAC: calculated as the difference between end-diastolic and end-systolic 
area of the right ventricle divided by end-diastolic area (16); 3) RVESRI: defined as the 
lateral wall to septal wall height ratio. The lateral wall length was measured from the 
lateral tricuspid annulus to the insertion point of the right ventricle on the interventricular 
septum. The septal height was measured as a straight line from the septal tricuspid annulus 
to the RV insertion on the interventricular septum (see also figure 1) (11); 4) Peak systolic 
tricuspid annular motion velocity (S’): S’ was measured with pulsed-wave tissue Doppler 
Imaging at the lateral free wall (17). In addition, the TAM to systolic pulmonary artery 
pressure (SPAP) ratio was calculated. SPAP was calculated by continuous Doppler 
imaging of the tricuspid valve insufficiency, measuring the peak systolic tricuspid 
transvalvular velocity plus right atrial pressure. Right atrial pressure was defined by 
inferior vena cava respiratory variability in its diameter, where a value of 5 mmHg was 
added if the inferior vena cava had a diameter < 17 mm and a normal inspiration excursion, 
a value of 10 mmHg if inferior vena cava had a diameter > 17 mm or an impaired 
inspiration excursion, or a value of 15 mmHg if inferior vena cava had a diameter > 17 mm 
and an impaired inspiration excursion (18). All measurements were performed by FM. 
Inter-observer and intra-observer variability for all the echocardiographic parameters of 
RV function were calculated in 10 randomly selected exams. A second observer (EG), who 
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was blinded to both the initial analysis and the CMR data repeated all measurements for 
quantification of inter-observer variability. 
Cardiac magnetic resonance imaging 
 Detailed information about the methodology of the CMR studies has been described 
elsewhere (19). Study patients were examined using a 1.5 T (Magnetom Symphony) or a 3 
T (Magnetom Trio, both from Siemens Medical Solutions, Erlangen, Germany) whole-
body clinical MRI system with cardiac synchronization by ECG electrodes. Ventricles 
were imaged from the base towards the apex during short end-expiratory breath-holds 
using contiguous short-axis slices in 8 mm increments. A cine steady-state free procession 
technique with retrospective gating was used. CMR analysis was done off-line on a 
dedicated workstation using commercially available software (ArgusVersion 4.01, Syngo 
MR B13, Siemens Medical Solutions, Erlangen, Germany) by two experienced observers 
(KW and AW). End-diastolic and end-systolic contours were manually traced for each 
slice. RV volumes were determined according to the modified Simpson’s rule (disk 
summation, no geometrical assumption). The stroke volume to endsystolic volume ratio 
was calculated as simplified evaluation of the Ees/Ea ratio (20). 
Study endpoints 
 The primary clinical endpoint of this study was defined as adverse event, i.e. a 
composite clinical endpoint consisting of death for any cause, hospitalization for 
worsening of PAH, start with i.v. prostanoid therapy, start with long term oxygen therapy, 
atrial septostomy or lung transplantation, whichever occurred first. This endpoint was used  
119 
 
 
 
 
 
in the GRIPHON trial (21). The secondary endpoint was defined as disease progression, 
i.e. a composite endpoint including a reduction in 6-MWD of more than 15%, 
accompanied by worsening in NYHA class or escalation of pulmonary vasodilator therapy, 
or increase in NT-Pro-BNP value by more than 50%, whichever occurred first.  
Statistical analysis 
Statistical analysis was performed with IBM SPSS Statistics v21.0. Categorical 
variables were reported as percentages. Continuous variables were reported as mean ± 
standard deviation (SD), and non-normally distributed continuous variables were presented 
as median and its interquartile range (IQR). Comparisons of interval changes in the 
echocardiographic and CMR parameters at baseline and follow-up were analyzed with a 
paired t-test. Comparisons between groups were performed using an un-paired t-test or the 
Mann-Whitney test for non-normally distributed variables. The correlation of the 
echocardiographic surrogates of RV function with CMR-derived RV EF was analyzed with 
a linear regression model. Receiver operating characteristic (ROC) analysis was performed 
with the echocardiographic parameters as test variables and RV EF by CMR as the state 
variable. Cox proportional hazard regression models were used to define the association of 
baseline imaging parameters or interval changes with the primary and secondary endpoints. 
Parameters with a p value < 0.1 were entered in a second step in a multivariate Cox 
proportion model. For calculating predictors of outcome from baseline parameters the 
maximal time of observation was used for the analysis. For calculating the predictive value 
of interval changes, the time from the last CMR to the last follow-up was used. In a time- 
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to-event analyses, endpoints were estimated with the use of the Kaplan-Meier method and 
were analyzed with the use of the log-rank test. Measurements of reproducibility were 
evaluated by calculating the interclass correlation coefficient (ICC)for observer agreement. 
A cut-off value > 0.75 indicated good agreement (22). In all analyses, the null hypothesis 
was rejected for p values < 0.05. 
 
Results 
Patients’ characteristics  
 Thirty-six patients (mean age 44 ± 16 years) were included in the study. Baseline 
characteristics of the patients are reported in table 1. Twenty-eight patients had pulmonary 
arterial hypertension (PAH) (n = 5 idiopathic PAH, n = 20 shunt-induced PAH, n = 3 PAH 
in association with connective tissue disease), 2 patients had combined pre- and 
postcapillary PH due to left heart disease, and 6 patients had not operable chronic 
thromboembolic PH (CTEPH). At the time of the first combined imaging exams, 30 (83%) 
patients were under treatment with disease targeted therapies: n = 23 (64%) patients were 
on vasodilator monotherapy, one of them on Calcium antagonists, n = 5 (14%) patients 
were under a dual therapy, and n = 2 (6%) patients received a triple therapy. The absence 
of therapy in the remaining 6 patients was due to their functional class (n = 3 with 
Eisenmenger syndrome and functional class I-II), intolerance to therapy (n = 1) and 
etiology of PH (n = 2 with PH due to left heart disease). During the follow up period, in 23 
patients (60%) a vasodilator was either newly introduced or added to the previous therapy. 
In 5 out of these 23 patients, i.v. prostanoid therapy was started.  
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 After a mean follow-up period of 57 ± 24 months, 14 patients (39%) reached the 
composite primary endpoint defined as adverse event: n=7 patients had to be hospitalized 
for worsening of PH, n=3 patients started with i.v. prostanoid therapy, 2 patients died for 
any cause, and 2 patients started long term oxygen therapy. In a Kaplan Meier analysis, the 
event free survival (Figure 2) at 2 years, 4 years, 6 years and 8 years was 91%, 83%, 54% 
and 20%, respectively. In addition, 30 patients reached the secondary endpoint, defined as 
disease progression: n=12 patients had an increase in nt-proBNP values by more than 50%, 
n=8 patients experienced an escalation of pulmonary vasodilator therapy, n=7 patients had 
a worsening in NYHA class, and n=3 patients had a reduction in 6-MWD of more than 
15% as first event. In a Kaplan Meier analysis, the survival without disease progression at 
2 years, 4 years, 6 years and 8 years was 91%, 61%, 16%, and 4% respectively (Figure 3).  
 
Comparison between echocardiographic parameters of RV function and CMR-derived 
RV ejection fraction at baseline.   
 There was only a weak correlation between echocardiographic parameters of RV 
function and CMR-derived RV EF. In a univariate linear regression analysis, a significant 
correlation was found between FAC and CMR-derived RV EF (r = 0.469, p = 0.003, 95% 
CI 0.190-0.855), but the correlation coefficient was low (Figure 4). No significant 
correlation was found for RVESRI and CMR-derived RV EF (r = 0.311, p = 0.057, 95% 
CI -29.407-0.435) (Figure 4). For the echocardiographic parameters of longitudinal RV 
contraction (S’ and TAM), there was again a significant but very weak correlation 
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observed with CMR-derived RV EF (r = 0.378, p = 0.005, 95% CI of 0.12-0.56 for S’, and 
r
 
= 0.341 with a p = 0.007, 95% CI of 0.09-0.5 for TAM) (Figure 4). 
 Figure 5 demonstrates the areas under the curve (AUC) of the corresponding ROC 
analysis with RV EF by CMR ≤ 40% as the state variable. The AUC was highest for FAC 
(AUC 0.791, 95% CI 0.672-0.910). A FAC value of 30% had a sensitivity of 86% and 
specificity of 58% to detect a RV-EF ≤ 40%. The others corresponding values for 
sensitivity and specificity for different cut-offs on the ROC curves are listed in the figure 
legend.   
 ICC for intra-observer variability for FAC, TAM, S’, and RVESRI were as follows: 
0.973, 0.999, 0.999, and 0.926, respectively. Inter-observer variability for the same 
parameters, also evaluated by ICC was 0.909, 0.934, 0.981, and 0.770, respectively. 
 
Predictive value of baseline parameters on endpoints 
 At baseline, there was no difference in age, gender, resting blood pressure, 6 minutes 
walking distance, and NT-proBNP levels in patients with and without an adverse event 
during follow-up. Patients with an adverse event had a lower BMI (23 ± 3 kg/m
2
 vs 27 ± 5 
kg/m
2
, p = 0.008) and lower oxygen saturation (88 ± 8% vs 93 ± 3%, p = 0.019), but 
higher resting heart rate (87 ± 11 bpm vs 76 ± 12 bpm, p = 0.008) at baseline compared to 
patients without event. Of note, the functional class at baseline was predictive of outcome 
(p = 0.002).  
Imaging parameters at baseline in both patient groups are presented in table 2. A  
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higher degree of tricuspid regurgitation and a higher SPAP at baseline were more often 
encountered in patients who reached the primary endpoint. As a consequence, the 
TAM/SPAP ratio was lower in patients with a worse outcome during follow-up. However, 
none of the echocardiographic surrogates of RV function and none of the CMR parameters 
of RV size and function were found to differ at baseline among patients who reached the 
primary endpoint or not. With respect to disease progression during follow-up, only RV 
cardiac output evaluated by CMR was lower in patients with vs. without disease 
progression (table 2). By univariate Cox regression analysis, none of the baseline 
parameters who different significantly between patients with and without adverse advent 
was predictive of an adverse event during follow-up nor of disease progression.  
 
Predictive value of interval changes parameters on endpoints 
Twenty patients had a combined echocardiographic and CMR follow up exam (4 
females / 16 males, mean age 43 ± 15 years) after a period of 47 ± 16 months. In the follow 
up group at the time of the second imaging exam, n = 17 (85%) patients were on specific 
pulmonary vasodilator therapies (n = 1 of them on Calcium antagonists, and n = 5 patients 
(25%) were on combination therapy with 2 or 3 vasodilators). A total of  n = 3 (15%)  
patients were still without disease targeted therapies because of their preserved functional 
class (NYHA I/II) in the setting of shunt-induced pulmonary hypertension. Four (20%) 
patients were in functional NYHA class III, n = 15 (75%) patients  in NYHA class II and n 
= 1 patient (5%) in NYHA class I.   
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Out of these n= 20 patients, n = 7 (35%) patients reached the primary endpoint after 
a mean follow up period of 14 ± 12 months: n = 5 patients died for any cause and n = 2 
patients had to be hospitalized for worsening of PAH.  
 At the time of the second imaging exam, there was no difference in age, gender, 
resting blood pressure, and 6 minutes walking distance in patients with and without an 
adverse event. Patients with an adverse event had however a lower BMI (22 ± 2 kg/m
2
 vs 
27 ± 5 kg/m
2
, p = 0.03), a lower oxygen saturation at rest (86 ± 8% vs 94 ± 2%, p = 0.004), 
but a higher resting heart rate (87 ± 6 bpm vs 72 ± 8 bpm, p < 0.001), worse functional 
class (NYHA III/II vs NYHA II/I, p = 0.032) and a higher Nt-proBNP value (2224 ± 2133 
ng/L vs 436 ± 433 ng/L, p = 0.015) compared to patients without events. 
Imaging interval changes between the baseline and follow-up exam in both patient 
groups are presented in table 3. Patients with a positive adverse event during follow-up 
showed from the first to second imaging exam a reduction of FAC, an increase of 
RVESRI,  and an increase in RV end diastolic volume. In a multivariate Cox regression 
analysis, only an increase in RV end diastolic volume was predictive of a subsequent 
adverse event. (table 4, table 5). In a log-rank analysis of the Kaplan-Meier survival 
estimates, patients who survived to the second follow-up exam but had an increase in RV 
end-diastolic volumes were more likely to have an adverse event during the subsequent 
follow-up period of 14 ± 12 months after the second imaging exam (log rank p = 0.006) 
(Figure 6).  
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Discussion 
 In this study with a small sample size, we could show that there is only a weak 
correlation between echocardiographic markers of right ventricular function and CMR-
based assessment of RV ejection fraction in PAH patients. In addition, baseline evaluation 
of right ventricular function by neither echocardiography nor CMR is predictive of long-
term outcome. However, interval changes over long period (4 years in our study) are 
predictive of further adverse events. Changes in RV volumes were more robust than 
changes in RV function for prognostication.   
Comparison between echocardiographic and CMR parameters of RV function 
Surrogates of RV systolic function are pre- and afterload dependent (23). In a 
chronically pressure loaded RV, the contribution of longitudinal shortening to ejection 
becomes less important than the contribution of circumferential contraction (24-25). In 
theory, echocardiographic surrogates relying exclusively on longitudinal shortening may 
be less accurate for quantification of systolic RV function in PAH patients compared to 
surrogates incorporating longitudinal and circumferential shortening. Our findings are in 
line with this hypothesis, the best – but still rather weak – correlation between 
echocardiography and CMR evaluation of RV function was found for FAC and RV-EF. 
Echocardiographic markers of longitudinal RV function (TAM or S’) had a lower AUC in 
the ROC curve than FAC.  
Some previous studies have shown a stronger correlation between  
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echocardiographic surrogates of RV function and CMR-derived RV-EF. In a recent study, 
Hoette et al. (23) compared TAM and FAC with RV-EF in a cohort of 54 patients with PH. 
They found a stronger correlation for both echocardiographic markers of RV function (r = 
0.81 and r = 0.63 respectively) compared to our study (r = 0.47 for FAC and r = 0.34 for 
TAM). As another example, also da Costa et al. (26) found a good correlation of 
echocardiographic surrogates of RV function with CMR-derived RV-EF (r = 0.61 for 
FAC, r = 0.59 for TAM, and r = 0.27 for S’) in a cohort of 66 PH patients. They identified 
global free wall RV strain as most reliable surrogate of CMR-derived RV-EF and as 
powerful predictor of long-term outcomes. All these studies, as the present, are limited by 
a rather small sample size, although the study of da Costa et al. has a larger cohort. 
Interobserver variations in measurement may contribute to discrepant findings. In addition, 
we studied echocardiographic pictures taken in the imaging laboratory during routine 
exams by not study-specific trained sonographers. This may additionally hamper the 
accuracy of RV function measurements but reflects more likely daily life experience. 
Baseline measures of RV function – echo and CMR – and their predictive power 
In our study, none of the clinical and echocardiographic, nor CMR parameters at 
baseline resulted predictors of endpoints. These data clash with some previous studies, 
where is well described a potential predictive role of some clinical, echocardiographic and 
CMR parameters on endpoints in PH patients. A previous study of Ghio et al. (27), 
evaluated 59 idiopathic PH patients. They found a prognostic role of some 
echocardiographic surrogates of RV function, in particular FAC and TAM in predicting a  
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worse survival (HR 0.004, 95% CI 0.002-0.62, and HR 0.91, 95% CI 0.83-0.99, 
respectively). These results are different from our study, where we did not found any 
baseline echocardiographic predictors of endpoints, maybe due to the different sample size 
and the different etiology of PH. On the other hand, in our study was evaluated the 
prognostic role of CMR parameter of RV function and dimension, not evaluated by Ghio et 
al. A more recent meta-analysis of 38 studies (28) evaluated the potential prognostic role 
of baseline echocardiographic surrogates of RV function in patients with heart failure with 
preserved ejection fraction, of whom 70% had PH. They found a prognostic role 
(predicting mortality) of FAC (HR 1.16, 95% CI 1.08-1.24) and TAM (HR 1.26, 95% CI 
1.16-1.38). These results are again different from ours, where we did not found any 
predictive value for baseline echocardiographic parameters. Differently from this meta-
analysis, we considered only PH patients, considering also a potential prognostic role of 
CMR parameters of RV function.  Amsellam et al. (11), evaluating 228 PH patients, 
studied the prognostic role of RVESRI, together with some clinical parameters, also 
studied in our study. At multivariable analysis, they found a prognostic role of higher 
functional class, higher value of NT-proBNP and of higher value of RVESRI. Differently 
from them, clinical, nor imaging parameters at baseline affected prognosis and outcomes. 
In the paper of Amsellam et al., the mean RVESRI for the whole study population was 
1.47 ± 0.19; a value of > 1.35 was indicative of adverse RV remodeling with impaired RV 
function and a value of > 1.70 indicated severely adverse RV remodeling with a further 
decline in RV function. In our study, the range value for RVESRI was 1.67-1.75, but  
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without impact on adverse events. The different impact of baseline value of RVESRI on 
prognosis between the study of Amsellam et al. and our study could be due to the smaller 
sample size of our research, considering also the similarity in primary endpoints evaluated 
in both the studies, although the study design was a bit different.  
Another new echocardiographic parameter was studied by Guazzi et al. (29), 
considering the TAM/SPAP ratio as independent predictor of worse outcomes. In their 
study they defined 3 tertiles of TAM/SPAP ratio (< 0.35, 0.35-0.57, > 0.57), considering 
the lowest value associated with lower pulmonary artery compliance and higher pulmonary 
vascular resistence. Different from this study, in our study, TAM/SPAP ratio at baseline 
was not predictive of outcomes, nor its interval change, although it resulted lower in 
patients with a worse outcome during follow-up, maybe due to the smaller cohort 
compared with those of Guazzi et al. 
The previously cited study of da Costa et al. (26), in a cohort of 66 PH patients and 
25 healthy controls, evaluated the prognostic role of some clinical parameters and of some 
echocardiographic parameters of RV function, and in particular RV strain, in patients with 
PH. In their study, after a mean follow up period of 3.3 years, they argued that not only a 
higher functional class, but also all the studied echocardiographic parameters could play a 
role in the prognostic evaluation of PH patients. Differently from them, in our study we did 
not evaluate 3D strain, without finding in clinical and echocardiographic parameters at 
baseline a prognostic role in predicting outcomes. On the other hand, we evaluated also the 
prognostic role of CMR-derived parameters of RV size and function, evaluating also  
interval changes of all the studied parameters. 
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Moceri et al. (10), studied, by 3D echocardiography, 104 PH patients and 34 
healthy controls, finding a prognostic role in predicting survival of 3D RV-EF, and 
RVEDV baseline values. In particular, they found a higher mean value of RVEDV in 
patients than in controls (91 ± 41 ml vs 51 ± 22 ml, p < 0.001), with a prognostic role of 
RVEDV in predicting survival (HR 1.02, 95% CI 1.01-1.03, p < 0.001). In line with our 
study, there is a prognostic role in RVEDV, but with several differences: first, the study of 
Moceri et al. is a 3D echocardiographic study, while we evaluated RV volumes by CMR. 
Then, in our study, we found a predictive role on outcomes for the indexed value of 
RVEDV, and finally, baseline value of RVEDVi did not predict adverse events.  
In a previous study, Yamada et al. (30), evaluated 121 CMR in PH patients with a 
mean follow up of 45 months. They defined as endpoints death and hospitalization for 
right heart failure. With a mean value of 123 ± 43 ml/m
2
, baseline value of RVEDVi was 
defined as predictor of mortality and hospitalization for right heart failure. These finding 
are very consistent with our study in considering RVEDVi as prognostic marker, with 
similar values of it. However, differently from Yamada et al., our study evaluated the role 
of interval change of RVEDVi in predicting outcomes, and consequently, the survival rate 
for the increase of RVEDVi.  
Finally, Swift et al. (31), in a large cohort of 576 PH patients, after a follow up 
period of 42 months, evaluated the specific role of baseline parameters of CMR in 
predicting prognosis. They found at univariate Cox regression analysis, that RV volumes 
(both RVEDV and RVEDVi) predicted mortality. However, in the multivariate analysis,  
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only increased RVESVi (and not the end-diastolic volume) was associated with a worst 
outcome. These results are quite similar with ours, where we defined a worst survival in 
patients with an increase in RVEDVi after a follow up period of 55 months, data not 
confirmed for RVESV. However, this study shows an important role of RV volumes, 
evaluated by CMR, in defining prognosis in patients with PH.  
Interval change measures of RV function – echo and CMR – and their predictive power 
 As widely discussed, we showed a prognostic role of RVEDVi increase from 
baseline to last follow up, confirming a worst prognosis in PH patients with higher value of 
RVEDVi after a second image exam. These results confirm the results of few previous 
studies, showing an important role of RV size changes during follow up in PH patients. In 
a previous CMR study, van Wolferen et al. (13) evaluated 64 PH patients, with a 1-year 
follow up in 54 patients, studying the prognostic role of several CMR parameters of RV 
function as predictor of mortality. Consistent with our study, they found a prognostic role 
of RVEDVi, with a poor prognosis in patients with a higher RVEDVi. In this study, they 
defined a mean value of RVEDVi of 85 ± 25 ml/m
2
, defining as independent predictor of 
prognosis not only RVEDVi at baseline, but also its change during follow up. They also 
showed a better survival in patients with a median value of RVEDVi at baseline < 84 
ml/m
2
. The results of van Wolferen et al., are very consistent with ours in defining a 
prognostic role of RV volumes, and in particular of RVEDVi. In our research, we defined a 
worst survival in patients who increased RVEDVi than in patients who did not. However, 
there are some differences between the 2 studies: the values of RVEDVi, that are higher in  
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our study (123 ± 64 ml/m
2
), and in our study, only interval change of RVEDVi resulted 
predictor of prognosis. Furthermore, in our study, we found an increase in RVEDV from 
baseline to follow up, while van Wolferen et al., found a decrease of it after 1-year of 
follow up, maybe due to a shorter follow up time compared with our study. Finally, in our 
study we focused also on some echocardiographic parameters of RV function, without 
finding any prognostic role of them.  
More consistently with our results, a meta-analysis of 8 studies (32), evaluated the 
impact of CMR parameters of RV size and function in predicting clinical deterioration in 
PH patients. They found a prognostic impact on mortality of RV-EF and of RVEDVi and 
RVESVi, defining a mortality rate per 5 ml/m
2
 of increase of RVEDVi. These results are 
very consistent with ours, where we defined a prognostic role of RVEDVi increase of at 
least 22 ml/m
2
, defined as median interval change responsible of bad prognosis. 
Finally, the previous cited study of Amsellam et al. (11), described a further 
worsening of prognosis in patients with an increase of RVESRI after 1-year follow. In our 
study, a value of RVESRI > 1.70, with an increase of at least 0.3 after follow up period, 
was associated with the presence of an adverse event. Nevertheless, these data were not 
confirmed by Cox regression analysis, where only the increase in RVEDVi resulted 
predictor of adverse event. 
Clinical implications 
The finding that an increase in RVEDVi is related with a worst survival is in line 
with some cited studies. It also confirms our hypothesis of superiority of CMR over  
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echocardiography in predict prognosis in PH patients. What is unexpected, is the 
prognostic role of only one CMR parameter, and of none of the echocardiographic 
parameters, or clinical parameters, such as oxygen saturation, NT-proBNP values and 
NYHA class. Although they have a clinical value in PH patients, in our study, also 
resulting lower (oxygen saturation) or higher (NT-proBNP and NYHA class) in patients 
with an adverse event, they did not result predictors of outcomes. Indeed, what we should 
expect, was a role of RV-EF as prognostic marker of outcomes (33), in addition to the 
prognostic role of the interval change between baseline and follow up of RVEDVi, defined 
as an increase of at least 22 ml/m
2
 from baseline to last follow up evaluation. However, 
also RV-EF did not predict outcomes both at baseline and after follow up. 
   
Limitations 
 This was a single center study, with a small sample size, with also a small number of 
patients making the second CMR, so these data should be confirmed by other centers to 
validate the results, and a larger cohort is warranted. Considering the prognostic role of 
echocardiographic surrogate of RV function, we did not evaluate 3D echocardiography and 
RV echocardiographic strain, that in several studies have shown a prognostic role in PH 
patients (9-11,26). 
 
Conclusions 
 In a cohort of 36 patients, followed up for a mean period of 57 ± 24 months, with a  
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number of 20 patients making a second CMR study, the increase of RVEDVi, evaluated by 
CMR, has a prognostic role, with a worst survival compared with patients who did not 
increase RVEDVi after treatment during follow up. None of the baseline imaging 
parameters of RV function, nor echocardiographic or other CMR interval changes (such as 
RV-EF) are predictive of outcomes. This study showed also a weak correlation between 
FAC, S’ and TAM and CMR-derived RV-EF, not found for RVESRI, defining so a weak 
diagnostic role of echocardiographic surrogates of RV function in PH patients. 
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Table 1. 
Patients’ baseline characteristics 
 All patients  Patients with a second 
CMR 
 n = 36 n = 20 
Age, years  44 ± 16 43 ± 15 
Women (%) 15 (42%) 4 (20%) 
BMI, kg/m
2
  25 ± 4 24 ± 5 
Systolic blood pressure, 
mmHg  
120 ± 14 122 ± 15 
Diastolic blood pressure, 
mmHg  
73 ± 10 74 ± 8 
Heart rate, bmp 80 ± 12 85 ± 11 
Oxy sat, % 91 ± 7 88 ± 9 
Six minute walk distance, m 450 ± 132 400 ± 138 
NT pro-BNP, ng/L 399, 191-977  493, 226-1269 
NYHA class I (%) 2 (6%) 0 (0%) 
NYHA class II (%) 26 (72%) 15 (75%) 
NYHA class III (%) 8 (22%) 5 (25%) 
Values are expressed as mean ± SD or number (percentage), or median and interquartile 
range (IQR). BMI: body mass index, BNP: brain natriuretic peptide, IQR: interquartile 
range. 
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Table 2. 
Univariate analysis for baseline values as predictor of adverse events and disease 
progression  
 Adverse event Disease progression 
 Positiv
e 
(n=14) 
Negati
ve 
(n=22) 
P 
valu
e 
Positive 
(n=30) 
Negativ
e 
(n=6) 
P 
val
ue 
 
ECHOCARDIOGRAPHY 
 
SPAP (mmHg) 86±20 51±21 < 
0.00
1 
64±27 55±18 0.5
28 
Tricuspid 
regurgitation 
grade 
2.3±0.
8 
1.4±0.6 0.00
1 
1.9±0.8 1.2±0.4 0.0
87 
FAC (%) 
 
35±14 36±9 0.92
0 
35±11 38±12 0.5
75 
TAM (mm) 
 
19±6 19±5 0.93
1 
19±6 16±4 0.2
56 
S’ (cm/s) 11±3.5 10±2.7 0.56
4 
11±3 10±2 0.7
44 
RVESRI 1.70±0
.36 
1.68±0.
22 
0.79
9 
1.67±0.
30 
1.75±0.
21 
0.6
04 
LV-EF 57.9±1
1.7 
60.7±9.
4 
0.42
9 
60.7±1
0.1 
54±9.9 0.1
48 
TAM/SPAP 0.2±0.
14 
0.4±0.2 0.01
2 
0.34±0.
23 
0.34±0.
1 
0.9
67 
 
Cardiac Magnetic Resonance 
 
RVEDVi (ml) 131±7
2 
118±60 0.56
4 
118±61 147±75 0.3
22 
RVESVi (ml) 75±56 64±40 0.51
8 
66±45 82±56 0.4
34 
CO (l/min) 8±2 7±3 0.46
4 
7±2 10±4 0.0
42 
RV-EF (%) 49.9±1
4.9 
47.8±1
1.5 
0.64
6 
48.9±1
3.5 
47.3±9.
1 
0.7
92 
LV-EF (%) 53.9±1
2.5 
58.8±1
0 
0.20
9 
57.1±1
1.5 
55.5±1
0.2 
0.7
49 
RV-SV/RVESV 0.99±0 1±0.5 0.88 1±0.5 0.94±0. 0.7
142 
 
 
 
 
 
.5 0 33 05 
Values are expressed as mean ± SD or number (percentage), or median and interquartile 
range (IQR). RA-RV: right atrial-right ventricular, SPAP: systolic pulmonary arterial 
pressure, FAC: fractional area change, TAM: tricuspid annular motion, S’: tricuspid 
annular systolic velocity, RVESRI: right ventricle end systolic remodeling index, LV-EF: 
left ventricle ejection fraction, CMR: cardiac magneti resonance imaging, RVEDVi: right 
ventricle end-diastolic volume indexed, RVESVi: right ventricle end-systolic volume 
indexed, CO: cardiac output, RV-EF: right ventricle ejection fraction, SV: stroke volume. 
 
 
 
Table 3. 
Univariate analysis for interval change values as predictor of adverse events and 
disease progression  
 Adverse event Disease progression 
 Positive 
(n=7) 
Negative 
(n=13) 
P 
value 
Positive 
(n=16) 
Negative 
(n=4) 
P 
value 
 
ECHOCARDIOGRAPHY 
 
Delta RA-
RV gradient  
0, -
6.2-
26.2 
-1, -10-0 0.335 0, -10-0 12.5, -
26.2-28.7 
0.505 
Delta SPAP 
(mmHg) 
0, 0-
28.7 
0, -20-0 0.088 0, -3.7-0 0, 0-25 0.999 
Delta FAC 
(%)  
8, -1-
19 
-8, -13.7-
1.7 
0.006 -2.5, -8-
7.7 
-3.5, -15-
7.2 
0.750 
Delta TAM 
(mm)  
4, 0-5 0, -3.5-2 0.056 1, -2.7-
3.7 
-0.5, -
2.5-2.2 
0.617 
Delta S’ 
(cm/s)  
0, -1-
0 
-1, -2-0 0.285 0, -2-0 -1, -2-0 0.912 
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Delta 
RVESRI  
-0.3, -
0.3-
0.2 
0.1, -0.1-
0.4 
0.003 -0.1, -
0.3-0.2 
0.1, -0.1-
0.4 
0.178 
Delta LV-
EF (%) 
4, -8-
5 
-5, -8-2 0.479 -2, -7-4 -6, -8-0 0.471 
 
Cardiac Magnetic Resonance 
 
Delta 
RVEDVi 
(ml/m
2
) 
-22, -
46-5 
2, -9-48 0.037 -8, 26-
13 
47, -4-
129 
0.099 
Delta 
RVESVi 
(ml/m
2
)  
-12, -
39-8.7 
-1, -6-43 0.106 -5, -16-
17 
-33, -1-
105 
0.124 
Delta CO 
(l/min)  
-0.2, -
0.9-
0.7 
-0.1, -
0.4-0.9 
0.639 -0.2, -
0.6-0.4 
6.1, 0-7 0.152 
Delta RV-
EF (%)  
-1, -3-
17 
-2, -7-3 0.311 -0.5, -5-
8 
-5, -14-1 0.122 
Delta LV-
EF (%) 
-3, -6-
10 
1, -4-8 0.757 2, -3-10 -9,-12-1 0.029 
Values are expressed as mean ± SD or number (percentage), or median and interquartile 
range (IQR). Delta values were obtained subtracting follow up values from baseline values. 
IQR: interquartile range, RA-RV: right atrial-right ventricular, SPAP: systolic pulmonary 
arterial pressure, FAC: fractional area change, TAM: tricuspid annular motion, S’: 
tricuspid annular systolic velocity, RVESRI: right ventricle end systolic remodeling index, 
LV-EF: left ventricle ejection fraction, CMR: cardiac magneti resonance imaging, 
RVEDVi: right ventricle end-diastolic volume indexed, RVESVi: right ventricle end-
systolic volume, CO: cardiac output, RV-EF: right ventricle ejection fraction. 
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Table 4. 
Univariate Cox regression model for interval changes parameters  
  Adverse event  
Variable HR 95% CI P 
value 
FAC  1.064 0.994-1.138 0.075 
RVESRI 0.116 0.011-1.247 0.075 
RVEDVi 0.943 0.905-0.983 0.005 
 HR: hazard ratio, CI: confidence interval, FAC: fractional area change, RVESRI: right 
ventricle end systolic remodeling index, RVEDVi: right ventricle end-diastolic volume 
indexed. 
 
 
Table 5. 
Multivariate Cox regression model for interval changes parameters 
                                                                                   Adverse event 
Variable HR 95% CI P value 
FAC 0.995 0.919-1.077 0.893 
RVESRI 0.265 0.007-10.549 0.480 
RVEDVi 0.945 0.900-0.993 0.024 
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HR: hazard ratio, CI: confidence interval, FAC: fractional area change, RVESRI: right 
ventricle end systolic remodeling index, RVEDVi: right ventricle end-diastolic volume 
indexed. 
 
 
 
Figures 
 
 
Figure 1. Representative echocardiographic images of the assessment of right ventricular 
systolic function: right ventricular end-systolic area for the assessment of RVESRI. 
RVESRI represents the ratio of end-systolic lateral length / septal height. 
RVESRI: right ventricle end systolic remodeling index. 
 
146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Kaplan Meier curve for event free survival rate for the composite primary 
endpoint defined as adverse event. 
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Figure 3. Kaplan Meier curve for event free disease progression rate. 
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Figure 4. Correlation coefficient depicted by linear regression graphic, showing the 
correlation between RV-EF evaluated by CMR and the four echocardiographic parameters 
of systolic RV function. 
RV: right ventricular, CMR: cardiac magnetic resonance. 
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Figure 5. 
Receiver operating characteristic analysis curves for the distinction by the four Doppler 
echocardiographic parameters examined in moderate to severe impaired RV-EF. (A) FAC; 
(B) TAM; (C) S’; (D) RVESRI. For every single parameter we considered three different 
cut-off values. For FAC, cut-off value of 33%, sensitivity 73% and specificity 58% (a); 
cut-off value of 30%, sensitivity 86% and specificity 58% (b); cut-off value of 28%, 
sensitivity 86% and specificity 47% (c). For TAM, cut-off value of 19 mm, sensitivity 49% 
and specificity 67% (a); cut-off value of 17 mm, sensitivity 65%, specificity 67% (b); cut-
off value of 15 mm, sensitivity 67% and specificity 44% (c). For S’, cut-off value of 10 
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cm/s, sensitivity 58% and specificity 87% (a); cut-off value of 9 cm/s, sensitivity 74% and 
specificity 73% (b); cut-off value of 8 cm/s, sensitivity 84% and specificity 60% (c). For 
RVESRI, cut-off value of 1.70, sensitivity 63% and specificity 66% (a); cut-off value of 
1.66, sensitivity 79% and specificity 61% (b); cut-off value of 1.61, sensitivity 79% and 
specificity 46% (c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Cumulative survival rate for the 2 groups of RV end-diastolic volume indexed 
increment.  
RVEDVi: right ventricle end-diastolic volume indexed. 
RVEDVi increase 
RVEDVi increase 
RVEDVi increase RVEDVi increase 
(months) 
Log Rank p = 0.006 
HR 0.945, 95% CI 0.900-0.993 
 
151 
 
 
 
 
 
CHAPTER 10.1. 
Predictors of cardiovascular outcomes in adult patients with repaired coarctation 
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Abstract 
Introduction: Coarctation of the aorta (CoA) is a congenital narrowing of the proximal 
descending aorta in the region of the ligamentum arteriosum. Despite the improvement in 
operative techniques, the prevalence of cardiovascular events and aortic re-interventions is 
still high. The aim of this study is to assess the incidence of adverse cardiovascular events 
in patients with repaired CoA, defining the predictors of outcomes in these patients. 
Methods: We retrospectively evaluated adult patients with repaired CoA by different 
techniques who underwent clinical and imaging follow-up evaluation. Primary endpoint 
was defined as the composite of death, heart failure, presence of atrial fibrillation, 
cerebrovascular ischemic events, coronary revascularization, aortic dissection, re-CoA 
requiring re-intervention and pseudoaneurysm formation. 
Results: Overall, 280 patients (112 females, 40%), age 33,6 ± 13,2 years were included in 
the study. After a follow-up period of 25,5 ± 12,7 years after CoA repair, composite 
clinical outcomes occurred in 29 patients (10%), where the more prevalent was the 
presence of atrial fibrillation (20; 7%). Composite outcome including re-CoA requiring an 
intervention and pseudoaneurysm formation, occurred in 116 patients (41%) after a mean 
follow-up period of 19,4 ± 13,6 years. 102 patients (36%) needed a second intervention for 
re-CoA. A pseudoaneurysm at the CoA site was diagnosed in 27 patients (10%) after a 
mean follow-up period of 24,9 ± 12,6 years. At multivariate Cox regression analysis, 
stenting procedure (HR 487.216, 95% CI 37.451-6338.445, p < 0.001) and older age at the 
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time at last follow up (HR 0.736, 95% CI 0.636-0.851, p < 0.001) were predictors of 
composite endpoint. 
Conclusions: stenting procedure, related to older age of CoA intervention and the presence 
of hypoplastic aortic arch play an important role in predict outcomes.    
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Introduction 
Aortic coarctation (CoA) is a congenital disease of the proximal descending aorta 
defined as a hemodynamic significant aortic obstruction, with an incidence of about 1 in 
2,500 live births, and a 2:1 predominance in males, accounting for 5–8% of children with 
congenital heart defects (1-3). The diagnosis of CoA is sometimes missed in infancy and 
childhood, and some subjects with a CoA are not detected until adult life, with a result of 
an high mortality rate in untreated patients (about 80% due to several complications, 
including aortic rupture, heart failure, and intracranial hemorrage) (1-2,4). In many cases, 
CoA is associated with a bicuspid aortic valve or a hypoplastic aortic arch and isthmus, but 
it can also be associated with Turner syndrome, or other congenital cardiac lesions like 
ventricular septal defect or large persistent arterial ductus arteriosus (PDA), or other more 
complex congenital heart disease (5). Today, to treat these patients from childhood to 
adulthood, surgical techniques comprise a large spectrum of different techniques (end-to-
end anastomosis, subclavian flap plasty, patch augmentation plasty, local implantation of 
an interposition graft or surgical creation of an extra-anatomic aortic ascending-to-
descending bypass (EAADB)), where percutaneous stent implantation is the preferred 
treatment in adult patients with focal native coarctation or focal restenosis (6-11).  
Late hypertension in patients after CoA repair is most oftenly associated with 
elevated sympathetic activity and endothelial dysfunction which play a role in the elevated 
risk for cardiovascular events in repaired CoA patients (12,13). Despite the well-known  
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improvements in operative techniques and associated with a more strict surveillance and 
management of residual arterial hypertension, comorbid cardiovascular diseases and CoA 
related complications, both, morbidity and mortality remain high, and is reported to be 
highest in patients with corrective interventions after 20 years of age (2,14). 
Furthermore, residual hypertension may lead to hypertensive cardiopathy with 
increased left ventricular (LV) wall thickness and mass, diastolic dysfunction, increased 
left atrial size and increased risk for atrial fibrillation (15). 
There is a reported risk for cerebral hemorrage due to aneurym of the cerebral 
arteries (3-5%), that generally involve the circle of Willis (berry aneurysms), where 
hypertension is not a necessary precondition for cerebral complication, and a reported risk 
of coronary artery disease (25-37%), that can be considered a common cause of early and 
late death in operated CoA patients (5).   
In addition, it is well known that aortic stiffness is increased in CoA patients, 
especially after late CoA repair (13). In the literature, it is reported that impaired aortic 
stiffness leads to a worse prognosis in CoA patients blood-pressure independenatly and 
could therefore be the force for increased mortality and morbidity. (16-19).  
The aim of this study was to assess the incidence of adverse cardiovascular events 
in adult patients with repaired CoA, and to define which echocardiographic and clinical 
variables, results by cardiac magnetic resonance (CMR) and computed tomography (CT) 
as well as different repair techniques predict adverse long-term clinical outcome. We also  
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focused on analysing the need for re-intervention for aotic re-stonosis and the presence of 
any pseudoaneurysm formation beeing small and under surveillance or a target for re-
intervention. 
 
Methods 
Study patients 
 We retrospectively evaluated 280 adult patients with repaired CoA which underwent 
clinical follow-up in three Swiss centers for Adult Congenital Heart Disease (ACHD). 
Overall, 122 patients from Zurich, 119 patients from Bern and 39 patients from Basel and 
included into the Swiss Adult Congenital HEart disease Registry (SACHER) (20) were 
used for our analysis. In our analysis, time and type of CoA repair technique, presence of 
other concomitant defects (i.e. bicuspid aortic valve, hypoplastic and/or Gothic arch, 
Turner syndrome), presence of other congenital defects (i.e. ventricular septal defects, and 
other congenital heart diseases) were accounted. Data from the most recent clinical 
evaluation with right cubital and leg office blood pressure measurements (left arm 
measurements in patients with a right-sided aortic arch), ambulatory 24-hour blood 
pressure measurement of the right arm (left arm measurements in patients with a right-
sided aortic arch) maximal exercise test with cubital blood pressure measurement (left arm 
measurements in patients with a right-sided aortic arch) and transthoracic 
echocardiography, type and dosage of the current anti-hypertensive medication were  
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recorded and included into our analysis. Two-hundred and twenty-five patients (80%) 
underwent a CMR with MR-aortography. In 32 patients (11%) an aortic angiography by 
CT-scan was performed due to presence of CMR-contra-indications.  
  
Adverse events 
A composite endpoint of death, heart failure, history or presence of atrial 
fibrillation, history of cerebrovascular ischemic and/or hemorrhagic events, coronary 
revascularization, aortic dissection, significant re-coarctation requiring re-intervention and 
pseudoaneurysm formation was defined. We divided our outcomes into clinical outcomes 
(death, heart failure, history or presence of atrial fibrillation, cerebrovascular ischemic 
and/or hemorrhagic events, coronary revascularization and aortic dissection) and CoA-
related outcomes (re-coarctation requiring re-intervention and focal pseudoaneurysm 
formation at the repair site). Re-coarctation requiring re-intervention was defined as the 
presence of a blood pressure gradient between upper and lower extremities > 20 mmHg, a 
diastolic “run-off” at Doppler echocardiography and a ≥ 50% aortic narrowing relative to 
the aortic diameter at the diaphragm level (by CMR or CT-scan) (21). The presence of a 
pseudoaneurysm was defined as dilation of the aorta due to disruption of the wall layers, 
which is only contained by the periaortic connective tissue (3,22). 
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Doppler echocardiography 
 Transthoracic Doppler echocardiography was performed by echocardiographers with 
expertise in ACHD using a 3.5 MHz transducer including second harmonic imaging. In all 
exams left atrium and left ventricular dimensions were measured, calculating left 
ventricular mass. Ascending aortic dimensions were measured for evaluation of aortic 
distension in the parasternal long axis view and calculated as (end-systolic diameter – end-
diastolic diameter)/(end-diastolic diameter) and aortic distensibility, defined as (aortic 
distension)/(systolic blood pressure – diastolic blood pressure). Ascending aorta was 
measured using the inner-edge-to-outer-edge method, at a distance of 4-6 centimeters from 
the aortic anulus. For evaluation of left ventricular systolic function, Simpson formula was 
used. Diaphragmatic aorta dimension and pulsed Doppler flow velocity signal were also 
obtained. Aortic arch diameter and aortic diameter at CoA site were measured using the 
inner-edge-to-inner-edge method, and aortic flow in the site of minumum diameter of CoA 
site (descending aorta) by both pulsed and continuous wave Doppler was measured, to 
search for presence or absence of a diastolic tail in the flow velocity curve. Pulse wave 
velocity (PWV) was evaluated by (center-line derived lenght of the aorta from aortic valve 
closing point to diaphragmatic aorta, assessed by CMR or CT))/(time delay between 
diaphragmatic foot wave and aortic valve foot wave. Diaphragmatic and aortic valve foot 
wave were obtained by pulsed wave Doppler, positioned to distal diaphragmatic aorta and 
closing point of aortic valve respectively). Aortic distension was acquired in 258 patients, 
aortic distensibility in 256 patients and PWV in only 142 patients, and all these parameters 
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were measured offline by FM. All other measurements were calculated online and data 
were collected retrospectively. 
Cardiac magnetic resonance imaging (CMR) and computed tomography (CT) 
 Study patients were examined using a 1.5 T or a 3 T whole-body clinical MRI system 
with cardiac synchronization by ECG electrodes. In 27 patients only a MR-angiography for 
the evaluation of aortic dimensions was performed, without the evaluation of ventricular 
volumes, function and mass. For all the other patients, ventricles were imaged from the 
base towards the apex during end-expiratory breath-holds by a stack of retrospectively 
ECG-triggered SSFP-cine sequence acquisitions. End-diastolic and end-systolic contours 
were manually traced for each slice offline to determine left ventricular volumes and mass 
according to the modified Simpson’s rule (disk summation). MR aortography using time-
adjusted contrast medium injection was used to assess aortic arch and descending aortic 
geometry, diameter and presence or absence of pseudoaneurysm or restenosis at CoA 
repair site. Reconstructed aortic 3D volumes were used for offline centerline assessment of 
the aortic length between the ascending (sinotubular junction site) and diaphragmal aorta 
for PWV calculations. Retrospectively gated steady-state free procession cine CMR 
images of the aortic arch, along with the ascending, transverse, descending and 
diaphragmatic aorta were routinely undertaken. Throughplane phase contrast flow 
measurements were acquired during breath-hold and in retrospectively ECG-gating 
technique in the ascending, diaphragmal and descending aorta at the CoA repair site and in  
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patients with a hypoplastic arch. Aortic distension of the ascending aorta was calculated as 
(maximum systolic area – maximum diastolic area)/(maximum diastolic area). Aortic 
distensibility of the ascending aorta was defined as (aortic distension)/(systolic blood 
pressure – diastolic blood pressure) after offline manually tracings of the maximal and 
minimal aortic areas within the acquired 25 frames. PWV was calculated as (length of the 
aorta, from sinotubular junction to diaphgramatic aorta, derived from the MR-
aortography)/(time delay between diaphragmatic foot wave and ascending aorta foot wave, 
derived from flow velocity measurements in the ascending and descending aorta). 
Measurements of aortic distension, aortic distensibility and PWV were calculated offline 
by FM. Unfortunately,  ascending aortic distension and aortic distensibility were acquired 
only in 100 patients due to missing cine data in the other patients. PWV was performed in 
only 81 patients due to missing flow acquisitions in the rest of the patients.  
 CT scan was performed in 32 patients who had contraindications to perform CMR. 
Patients were examined while supine, taking images extending from the base of the neck to 
the diaphragm, using retrospective ECG-gated cardiac CT scanning. A 64-slices CT-scan 
was used, with a slice thickness of 1 mm and a reconstruction interval of 0.75 mm. A 3D 
reconstruction of the complete aorta was obtained, allowing measurement of the diameter 
of aorta from ascending to diaphragmatic portion. The length of the aorta from the 
ascending to the diaphragmal aorta derived from center-line measurements were used for 
the calculation of PWR by echo Doppler flow profiles. 
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Statistical analysis 
 Categorical variables are reported as absolute numbers and percentages. Continuous 
variables are reported as mean ± standard deviation (SD), and non-normally distributed 
continuous variables as median and interquartile range (IQR). Chi-square test and Fisher’s 
exact test were used to compare pseudoaneurysm formation in patients among intervention 
types. Univariate Cox proportional hazard regression model was used to assess the 
association between clinical, echocardiographic, CMR, and CT-scan variables and adverse 
outcomes. Variables with p < 0.10 at univariate analysis were included as covariates into 
the multivariate Cox regression models to test which variables were independently 
associated with the outcomes. Statistical significance in the multivariate analysis was 
defined for a p value < 0.05 and hazard ratios and their 95% confidence intervals are 
presented. In time-to-event analyses, outcomes were estimated with the use of the Kaplan-
Meier method and were analyzed by a log-rank test. Statistical analysis were performed 
with IBM SPSS Statistics v25.0 (Armonk, New York, United States of America). 
 
Results 
Clinical and imaging results  
Two-hundred and eighty patients (112 females, 40%), mean age of 33,6 ± 13,2, 
were included into the study. Baseline characteristics of the patients are reported in table 1. 
In our cohort, the more prevalent type of first intervention was end-to-end anastomosis 
(64%), followed by stenting procedure (14%) (figure 1). One-hundred and eighty-seven  
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patients had a concomitant bicuspid aortic valve (67%), and a hypoplastic aortic arch 
(defined as a diameter of less than 50% of the diameter of the ascending aorta) (10,23) was 
present in 132 patients (47%). One-hundred and thirty-four patients were under anti-
hypertensive treatment (48%). Thirty-eight patients were under anti-hypertensive mono-
therapy, 54 were treated with dual therapy, 31 with triple-therapy and 11 patients needed a 
combination with four or more antihypertensive agents. 
 24-hour ambulatory blood pressure monitoring was performed in 141 patients, where 
nocturnal impaired blood pressure response in the whole population was found in 45 
patients (16%), and nocturnal impaired blood pressure response in normotensive patients 
was found only in 14 patients (5%). Exercise test was performed in 210 patients, of whom 
167 reached the peak of the exercise (defined at least 85% of the maximal expected heart 
rate). The mean blood pressure profile at exercise peak was 205 ± 34 mmHg for systolic 
blood pressure and 80 ± 15 mmHg for diastolic blood pressure. An echocardiographic 
exam was performed in 278 patients. Dilated left atrium was found in 54 patients (19%). 
We found left ventricular hypertrophy in 59 patients (21%), defined as a left ventricular 
mass > 95 g/m
2 
in females and 115 g/m
2
 in males. Twelve patients (4%) had a left 
ventricular dysfunction, defined as a left ventricular ejection fraction evaluated by Simpson 
biplane ≤ 50%. The mean value of CoA site diameter evaluated by echocardiography was 
13 ± 3 mm, and only 8 patients (3%) had an echo-diastolic tail. Mean value of PWV 
evaluated by echocardiography was 10.9 ± 6.4 m/s. In the 225 CMR, 44 patients had a 
dilated left atrium (20%), 50 patients had a left ventricular hypertrophy (22%), and 9  
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patients (4%) had a left ventricular dysfunction. The mean value of CoA site diameter 
evaluated by CMR was 14 ± 3 mm, with only 8 patients (4%) with a diastolic tail at CoA 
site. Collaterals at CMR were found in 16 patients (7%). Mean value of PWV evaluated by 
CMR was 10.9 ± 8.8 m/s.  Finally, the mean value of aorta diameter evaluated by CT-scan 
was 17 ± 7 mm.   
 
Cardiovascular events  
After a mean follow up period of 25,5 ± 12,7 years after first intervention for CoA 
repair, composite adverse events occurred in 29 patients (10%). Atrial fibrillation was the 
most prevalent adverse outcome (20; 7%) and was diagnosed in the older patients (mean 
age 53,9 ± 16.1 years) (table 2) (figure 2). Results of the univariate and multivariate Cox 
proportional hazard regression model are reported in tables 4-8. By multivariate Cox 
regression analysis, aortic stenting procedure, age of repair > 1 year, and older age at last 
follow up were independent predictors of the composite primary endpoint. Older age at 
first CoA repair (> 12 years) (but not an age of repair > 1 year) is an independent predictor 
of composite adverse clinical outcomes and of the presence of atrial fibrillation (> 7,7 
years). Impaired aortic distension evaluated by transthoracic echocardiography on 
ascending aorta, is associated with adverse composite clinical outcomes. None of the other 
echocardiographic and CMR parameters, nor aortic stiffness retrospectively evaluated by 
CMR, or residual hypertension statistically affected outcomes by multivariate analysis. 
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Re-coarctation and pseudoaneurysm formation 
CoA-related adverse outcomes (significant re-CoA requiring re-intervention or 
pseudoaneurysm at the CoA-repair site), occurred in 116 patients (41%) (table 3) (figure 
3). Significant re-CoA requiring re-interventions was diagnosed in 102 patients (36%) after 
a mean follow-up time of 19,4 ± 13,6 years after first repair. From these 102 patients, 55 
were treated by aortic stenting (54%); in 18 patients a surgically creation of an EAADB 
was performed (18%); 17 patients were operated by an aortic patch plasty (17%); in 6 
patients an interposition graft was implanted (6%); 5 patients were treated by an end-to-
end anastomosis (5%); and 1 patient was repaired by subclavian flap plasty technique 
(1%). Finally, 25 patients (9%) received a third operation due to severe re-re-CoA. From 
these, 13 patients were treated by stenting (52%), 4 patients by EAADB (16%), 3 patients 
by end-to-end anastomosis (12%), 3 patients by aortic patch plasty (12%) and 2 patients 
received an interposition graft (8%).  
 A pseudoaneurysm was detected by CMR or CT in overall 27 patients (10%) after a 
mean follow-up time of 24,9 ± 12,6 years after first CoA repair. In 11 patients that had 
performed an end-to-end anastomosis (6%) was detected a pseudoaneurysm. Seven 
patients operated by aortic patch plasty procedure (32%) experienced a pseudoaneurysm 
and in 5 patients who had received a stenting procedure (13%) was found a 
pseudoaneurysm. The prevalence of pseudoaneurysm formation was not statistically 
different between patients treated with an aortic patch plasty procedure or stenting 
procedure, although pseudoaneurysm was more prevalent in patients operated by aortic  
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patch plasty procedure (p = 0.283). The mean size of pseudoaneurysm was 21 ± 18 mm. 
Pseudoaneurysm size progression was reported in 5 patients. Of 27 pseudoaneurysms, 9 
(33%) patients went to a re-intervention due to large and progressive size of the 
pseudoaneurysm. Of these 9 patients, 5 were treated with surgically exclusion of the 
pseudoaneurysm and creation of an extra-anatomic ascending-to-descending aortic bypass 
(56%), whereas 3 patients were treated by insertion of a local interposition graft (33%) and 
1 patient was treated by aortic stenting procedure (11%). 
 By multivariate analysis, stenting procedure as the first CoA-repair technique also is 
an independent predictor for re-CoA requiring re-intervention, and pseudoaneurysm 
formation of any size. Older age at first CoA repair (> 8 years) (but not an age of repair > 1 
year) predicts the occurrence of significant re-CoA. The presence of a hypoplastic aortic 
arch is statistically associated with the higher risk of pseudoaneurysm formation.  
 Kaplan-Meier curves show and confirm a higher prevalence of composite primary 
endpoint (figure 4), of severe re-CoA (figure 5) and of pseudoaneurysm formation (figure 
6) in patients treated by stenting procedure. Finally, by Kaplan-Meier curves also a higher 
prevalence of pseudoaneurysm formation (figure 7) in patients with a hypoplastic aortic 
arch was shown and confirmed. 
  
 
Discussion 
 This multicentric study, made on 280 adult patients with repaired CoA, showed a high  
167 
 
 
 
 
 
incidence of severe re-CoA requiring re-intervention (36%), with a lower incidence of 
pseudoaneurysm formation (10%), and a very low incidence of clinical outcomes, of which 
the most frequent was atrial fibrillation (7%). Several clinical, surgical and imaging 
variables resulted predictive of outcomes at univariate analysis, moreover, at multivariate 
analysis, stenting procedure showed to play an important role in affect composite primary 
endpoint, severe re-CoA requiring re-intervention and pseudoaneurysm formation. 
Clinical outcomes  
Our results showed a lower mortality rate compared with some previous studies 
(11-12). In fact, in our study, we found a mortality rate of 0,4%. Brown et al (2), in 819 
patients with isolated CoA, described an overall early mortality rate of 2,4%, with a 
survival rates of 93,3%, 86,4%, and 73,5% at 10, 20 and 30 years, respectively. Larger 
cohort of Brown at al could explain the higher mortality rate of their study. In a less recent 
study, Hager et al (24), in a cohort of 191 repaired CoA, found a mortality rate of 2,6%. 
However, in their study, death registered were related to intervention complications. More 
recently, Bambul Heck et al (14), studied 143 patients with isolated CoA, finding a 
mortality rate of about 6%. In this study, patients enrolled were older than in our study, and 
this could explain the quite higher mortality rate. Always comparing our results with the 
study of Bambul Heck et al (14), in our study, we found a major total number of clinical 
outcomes, in particular of atrial fibrillation (there are no data about this outcome in 
literature), but also of cerebrovascular events (9 vs. 2) and aortic dissection (3 vs. 1). 
Maybe these results could be due to the larger population of our study. Also for coronary  
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revascularization (with a rate of 1,4% in our study) there are no studies in literature. 
Instead is well known the association between left-sided congenital heart diseases and 
heart failure (in particular also for CoA) (25). 
Re-coarctation and pseudoaneurysm outcomes  
Regarding CoA-related outcomes, in our study we found a higher restenosis rate in 
CoA site compared to previous studies, although there are few recent data in literature. In 
particular, Hager et al (24), described a restenosis rate of 17%, lower when compared to 
36% found in our study. Considering type of intervention and related restenosis in our 
population, restenosis was present in 71 patients operated by end-to-end anastomosis, in 11 
patients after stenting procedure, in 11 patients that had received aortic patch plasty, in 7 
patients with subclavian flap repair and 1 patient with ascending-to-descending bypass or 
interposition graft. In our study, by multivariate analysis, stenting procedure and an older 
age (> 8 years) at first CoA repair resulted predictive of restenosis. Chen et al (26), in a 
population of 247 adult operated CoA patients, found a restenosis rate of 31%, more 
prevalent in patients operated when younger and that had received an end-to-end 
anastomosis. In line with our study, there was an overall higher prevalence of restenosis in 
end-to-end anastomosis patients, but differently from their study, in our study, stenting 
procedure, and an older age at first CoA repair resulted as predictor of restenosis. The 
study of Chen et al is in line with the paper of Brown et al (2), where they found a higher 
rate of re-CoA requiring re-intervention in patients younger at time of first intervention and 
underwent to end-to-end anastomosis. It is well known that younger age at first CoA repair  
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should be considered as risk factor for re-CoA, maybe due to a severe CoA in patients 
diagnosed at young age. However, differently from these 2 studies, in our study, the higher 
rate of re-intervention was found in patients with an age > 8 years at first CoA repair. It is 
known that children that receive stenting for CoA have a restenosis rate of 18% (27), and 
this is quite in line with our study, where we had 15 stenting procedure performed < 18 
years. This first consideration could explain the difference of our study from the previous 2 
cited studies, where Chen et al performed stenting procedure only in adult patients, and 
Brown et al did not evaluate stenting procedure. On the other hand, when stenting 
procedure is performed during adulthood, there is a progressive increase of restenosis year 
by year of follow-up (27), and also this consideration is consistent with our study, where 
we had a longer follow-up compared to the study of Chen et al. 
Moreover, maybe due to a mean older age of our patients, as a new finding 
compared with previous studies, stenting procedure resulted predictor of restenosis, where 
the study of Brown et al did not evaluate interventional procedure for CoA repair.  
 In our study, we found an incidence of pseudoaneurysm formation of 10%, which was 
more prevalent in end-to-end anastomosis, followed by aortic patch plasty and stenting 
procedure (although without a statistical significant difference). Considering previous 
studies, Chen et al (26), found a pseudoaneurysm formation rate of 13%, more frequent 
after aortic patch plasty. These results are in line with our study, but differently from them, 
maybe due also in this situation to the older age of repair, in our study, stenting procedure 
was found as predictor of pseudoaneurysm formation, together with the presence of  
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hypoplastic aortic arch, that in the study of Chen et al did not influence pseudoaneurysm 
formation. In another study, Cramer et al (28), studied 63 patients undergone to aortic 
patch plasty operation, finding a very high incidence of pseudoaneurysm formation (47%). 
This study suggest the great impact of aortic patch plasty intervention on pseudoaneurysm 
formation, but differently from our study, Cramer et al did not evaluate patients that had 
received other types of intervention, with a consequent small sample size compared to our 
study. On the other hand, Hoffman et al (29), found pseudoaneurysm formation in 28 of 
399 patients operated for CoA. Differently from other studies, they found a higher 
prevalence of pseudoaneurysm in patients treated by stenting procedure than in patients 
receiving surgery (13% vs. 4% respectively, p < 0.05), with a predictive value of stenting 
procedure on pseudoaneurysm formation at Cox analysis (HR 6.00, 95% CI 2.60-13.84, p 
< 0.001). These data are in line with our study, where we found a predictive value of 
stenting procedure on pseudoaneurysm formation. 
 
Limitations 
 This is a retrospective study, with a relative small sample size, with a small number of 
outcomes, which could affect the statistical results of our analysis. On the other hand, the 
different time of intervention for each operation, in particular for stenting procedure, that 
generally is performed in adult age, could affect some results, explaining a statistical 
significance for it compared to other interventions, such as aortic patch plasty, in which, 
although was found a major incidence of pseudoaneurysm formation (however not  
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statistically different), resulted not statistically related to it. In addition, considering aortic 
stiffness, it was evaluated in a poor number of patients by CMR, and also by echo, PWV 
was evaluable only in about half of the entire population. This could be a reason of loss of 
power for aortic stiffness in predictive value on outcomes. Finally, the different time of 
follow up, with a quite strict follow up after stenting procedure, compared to other surgical 
procedures, could affect our results. 
 
Conclusions 
 In a cohort of 280 patients from 3 Swiss ACHD centers, was found a high incidence of 
severe re-coarctation, requiring an intervention, with a lower incidence of pseudoaneurysm 
formation, with a consequent and unexpected role of stenting procedure, related to older 
age of CoA intervention and the presence of hypoplastic aortic arch in predict outcomes.  
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Table 1. Patients’ characteristics 
 Patients (n = 280)  
Age (years) (range) 33,6 ± 13,2 (17,1-84,5) 
Female  112 (40%) 
BSA (m
2
) 1,84 ± 0,23 
BMI (Kg/m
2
) 25,4 ± 10,2 
Age at first intervention (years) (range) 3,6 (0,1-59,7) 
Systolic blood pressure (mmHg) 129 ± 14 right arm, or left arm if right 
arch 
Diastolic blood pressure (mmHg) 73 ± 11 right arm, or left arm if right 
arch 
Leg blood pressure (mmHg) 124 ± 16 
Type of primary coarctation intervention  
     End-to-end anastomosis  181 (64%) 
     Stenting  39 (14%) 
     Aortic patch plasty  22 (8%) 
     Subclavian flap-repair  22 (8%) 
     Ascending-to-descending bypass  11 (4%) 
     Interposition graft 5 (2%) 
Bicuspid aortic valve  187 (67%) 
Hypoplastic aortic arch  132 (47%) 
Gothic arch  37 (13%) 
Ventricular septal defect  57 (20%) 
Other congenital heart disease  52 (19%) 
     Congenital valvular aortic stenosis  16 (6%)  
     Atrial septal defect  13 (5%) 
     Taussig-Bing Heart  6 (2%) 
     Transposition of the great arteries  3 (1%) 
     Pulmonary stenosis  3 (1%) 
     Aorto-pulmonary window  2 (0.7%) 
     Severe mitral valve prolapse  2 (0.7%) 
     Mitral stenosis  2 (0.7%) 
     Anomalous coronary artery origin  1 (0.4%) 
     Double orifice mitral valve  1 (0.4%) 
     Ebstein syndrome  1 (0.4%) 
     Tetralogy of Fallot  1 (0.4%) 
     Double inlet left ventricle  1 (0.4%) 
Turner syndrome  10 (4%) 
Anti-hypertensive treatment  134 (48%) 
     Beta-blockers  67 (50%) 
     ACE-i  51 (38%) 
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     ARBs  66 (49%) 
     Calcium-antagonists  56 (42%) 
     Diuretics  42 (31%) 
     Alpha-blockers  1 (0,7%) 
BSA: body surface area; BMI: body mass index; ACE-i: angiotensin converting enzyme 
inhibitors; ARBs: angiotensin II receptor blockers. 
 
 
Table 2. Clinical outcomes 
 Patients (n = 280) 
Clinical Outcomes  29 (10%) 
     Death  1 (0,4%) 
     Atrial fibrillation  20 (7%) 
     Cerebrovascular events  9 (3%) 
     Coronary revascularization  4 (1,4%) 
     Heart failure  5 (1,8%) 
     Aortic dissection  3 (1%) 
 
Table 3. Coarctation-related outcomes 
 Patients (n = 280) 
Coarctation-related outcomes  116 (41%) 
     Severe re-coarctation needing re-
intervention  
102 (36%) 
     Pseudoaneurysm formation  27 (10%) 
Categorical variables reported as absolute numbers and percentages. Continuous variables 
reported as mean ± standard deviation, and non-normally distributed continuous variables 
presented as median and interquartile range (IQR). 
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Table 4. Cox analysis of composite endpoint 
Univariate analysis composite primary endpoint 
Variables HR 95%CI P value 
Age 0.872 0.844-0.900 <0.001 
Sex 0.657 0.457-0.943 0.023 
Age at repair (>1 
vs < 1 year) 
0.621 0.430-0.897 0.011 
Stenting 
procedure 
29.798 14.600-60.814 <0.001 
Presence of 
bicuspid aortic 
valve 
0.695 0.486-0.993 0.046 
Presence of 
hypoplastic 
aortic arch 
1.626 1.151-2.297 0.006 
Dilated echo LA  0.574 0.379-0.872 0.009 
Echo LV mass i 0.994 0.989-1.000 0.039 
Echo CW peak 
at CoA site 
1.005 1.001-1.008 0.005 
Presence of echo 
diastolic 
dysfunction 
0.390 0.108-0.731 0.003 
Echo aortic 
distension 
207.632 11.558-3729.853 <0.001 
Dilated CMR 
LA 
0.508 0.305-0.847 0.009 
CMR aortic 
distension 
4.277 1.170-15.636 0.028 
Multivariate analysis primary endpoint 
Variables HR 95%CI P value 
Age 0.636 0.510-0.793 <0.001 
Age at repair (>1 
vs < 1 year) 
6.002 1.442-24.975 0.014 
Stenting 
procedure 
1180.009 50.271-27698.551 <0.001 
HR: hazard ratio; CI: confidence intervals; LV: left ventricular; LA: left atrium; CW: 
continue wave; CMR: cardiac magnetic resonance.  
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Table 5. Cox analysis for clinical outcomes 
Univariate analysis clinical outcomes 
Variables HR 95%CI P value 
Age of first CoA 
repair 
1.052 1.018-1.087 0.002 
Interposition 
graft procedure 
8.922 1.916-41.553 0.005 
Dilated echo LA  2.277 1.029-5.036 0.042 
Echo aortic 
distension 
6052.482 6.344-
5774652.373 
0.013 
Multivariate analysis clinical outcomes 
Variables HR 95%CI P value 
Age of first CoA 
repair 
1.061 1.013-1.112 0.013 
Echo aortic 
distension 
78792.756 44.080-
140843099.7 
0.003 
HR: hazard ration; CI: confidence intervals; CoA: coarctation; LA: left atrium. 
 
Table 6. Cox analysis for atrial fibrillation 
Univariate analysis atrial fibrillation 
Variables HR 95%CI P value 
Interposition 
graft procedure 
16.237 3.107-84.857 0.001 
Age of first CoA 
repair 
1.068 1.030-1.107 <0.001 
Echo LV mass i 1.015 1.001-1.029 0.034 
Multivariate analysis atrial fibrillation 
Variables HR 95%CI P value 
Age of first CoA 
repair 
1.075 1.012-1.142 0.020 
HR: hazard ratio; CI: confidence intervals; CoA: coarctation; LV: left ventricular. 
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Table 7. Cox analysis for re-coarctation 
Univariate analysis re-coarctation 
Variables HR 95%CI P value 
Age 0.973 0.956-0.990 0.002 
Sex 0.607 0.398-0.928 0.021 
Stenting 
procedure 
2.123 1.097-4.106 0.025 
Age of first CoA 
repair 
0.952 0.921-0.983 0.003 
Age at repair (>1 
vs < 1 year) 
0.501 0.337-0.745 0.001 
Presence of 
hypoplasic aortic 
arch  
1.678 1.130-2.490 0.010 
Echo CW peak 
at CoA site 
1.005 1.001-1.008 0.011 
Multivariate analysis re-coarctation 
Variables HR 95%CI P value 
Stenting 
procedure 
7.930 2.768-22.713 <0.001 
Age of first CoA 
repair 
0.934 0.876-0.996 0.037 
HR: hazard ratio; CI: confidence intervals; CoA: coarctation; CW: continue wave. 
 
Table 8. Cox analysis for pseudoaneurysm formation 
Univariate analysis pseudoaneurysm formation 
Variables HR 95%CI P value 
Age of first CoA 
repair 
1.040 1.007-1.074 0.018 
End-to-end 
anastomosis 
procedure 
0.257 0.119-0.556 0.001 
Stenting 
procedure 
14.573 4.000-53.097 <0.001 
Interposition 
graft procedure 
6.286 1.443-27.376 0.014 
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Presence of 
hypoplastic 
aortic arch  
3.674 1.605-8.413 0.002 
Multivariate analysis pseudoaneurysm formation 
Variables HR 95%CI P value 
Stenting 
procedure 
6.401 1.511-27.119 0.012 
Presence of 
hypoplastic 
aortic arch 
3.816 1.561-9.325 0.003 
 HR: hazard ratio; CI: confidence intervals; CoA: coarctation. 
 
Figures 
 
Figure 1. Distribution of type of CoA intervention 
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Figure 2. Distribution of clinical outcomes 
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Figure 3. Distribution of coarctation-related outcomes 
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Figure 4. Kaplan-Meier curve for stenting procedure and composite primary endpoint.  
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Figure 5. Kaplan-Meier curve for stenting procedure and severe re-coarctation 
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Figure 6. Kaplan-Meier curve for stenting procedure and pseudoaneurysm formation 
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Figure 7. Kaplan-Meier curve for presence of hypoplastic aortic arch and pseudoaneurysm 
formation 
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Blood pressure profile evaluated by ambulatory measurement and ambulatory blood 
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Abstract 
Introduction: Aortic coarctation (CoA) is a congenital disease, characterized by 
narrowing and obstruction of descending aorta, with a high prevalence of post-
interventional residual arterial hypertension. The aim of this study is to assess the blood 
pressure profile in operated CoA patients. 
Methods: We retrospectively evaluated 280 adult patients with repaired CoA with 
different techniques. All patients underwent to clinical and imaging evaluation, with great 
attention to blood pressure profile, considering also ambulatory blood pressure monitoring 
(ABPM) for the evaluation of nocturnal blood pressure profile. 
Results: Two-hundred and eighty patients (112 females, 40%), mean age of 33,6 ± 13,2, 
were included in the study. After a mean follow-up period of 20,1 ± 13,1 years, residual 
arterial hypertension was found in 137 patients (49%), nocturnal impaired blood pressure 
response in the whole population was found in 45 patients (16%). At multivariate Cox 
regression analysis, male patients, (HR 0.409, 95% CI 0.240-0.698, p = 0.001), patients 
with an older age (HR 0.874, 95% CI 0.837-0.913, p < 0.001), patients 8 years of age or 
older at the age of first CoA repair (HR 1.184, 95% CI 1.133-1.238, p < 0.001) resulted at 
higher risk of residual arterial hypertension. 
Conclusions: In patients with repaired CoA there is a great prevalence of residual arterial 
hypertension, related to older age at time of first intervention and at follow-up, with an also 
quite great prevalence of impaired nocturnal blood pressure response, evaluated by ABPM. 
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Introduction 
 Aortic coarctation (CoA) is a congenital disease of the proximal descending aorta, 
characterized by a hemodynamic significant aortic narrowing and obstruction, frequently 
associated with diffuse hypoplasia of the aortic arch, the presence of gothic arch, the 
presence of bicuspid aortic valve or other congenital cardiac lesions, and is often related to 
Turner syndrome (1). The greatest part of CoA patients are treated in infancy or childhood 
by different surgical options, but percutaneous stent implantation is nowadays the preferred 
treatment in adult patients with a delay of diagnosis, or in not complicated forms that arrive 
to adulthood, but also for focal restenosis (2-5).  
The improvements in operation techniques, just few reflected the reduction in 
outcomes incidence in CoA patients, where is still present a high prevalence of 
cardiovascular events, but also of re-intervention for severe re-coarctation (13%), and for 
pseudoaneurysm formation (9%) (1,6,7). High morbidity and mortality found in several 
studies (6,7), is strongly related to the high incidence of severe arterial hypertension 
present in CoA patients. In fact, the elevated risk for cardiovascular events can be 
explained by persistent elevated sympathetic activity, endothelial dysfunction, and late 
hypertension in patients after CoA repair (8,9). Based on this assumption, the major 
complication and determinant of mortality after repair of CoA is the high incidence of late 
arterial hypertension, which may be present in 20-60% of patients with successful repair 
and without restenosis (6-8,10).  
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 On the other hand, there is an important role played by aortic stiffness on morbidity 
and mortality, that independently from the presence of arterial hypertension, can have an 
impact on blood pressure (11-15), becoming both cause and effect of late hypertension, 
and has been shown to be increased in CoA patients late after repair (9).  
 The aim of this study was to assess the prevalence of residual hypertension, 
considering also the prevalence of non-dipper patients evaluated by ambulatory blood 
pressure monitoring (ABPM), defining the predictors of hypertension and of impaired 
nocturnal blood pressure response in these patients. 
 
Methods 
Study patients 
 We retrospectively evaluated 280 adult patients with repaired CoA by 3 different 
centers (122 patients from Zurich, 119 from Bern and 39 from Basel), belonging to the 
Swiss Adult Congenital HEart disease Registry (SACHER) (16). All patients underwent to 
a clinical evaluation, including right cubital and leg office blood pressure measurements 
(left arm measurements in patients with a right-sided aortic arch), considering as presence 
of hypertension, according to actual guidelines (17-18) a value ≥ 140/90 mmHg after an 
ambulatory measurement, and ABPM of the right arm (left arm measurements in patients 
with a right-sided aortic arch). ABPM was performed in 141 patients (50,4%), evaluating  
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the nocturnal blood pressure response in the whole population and in normotensive 
patients. Dipper subjects were defined for a physiological nocturnal reduction in blood 
pressure values from 10% to 20% (18). Maximal exercise test with cubital blood pressure 
measurement (left arm measurements in patients with a right-sided aortic arch) and 
transthoracic echocardiography, type and dosage of the current anti-hypertensive 
medication were recorded and included into our analysis. Two-hundred and twenty-five 
patients (80%) underwent to a CMR (in 55 patients (20%). CMR was not performed due to 
the presence of a pacemaker or for claustrophoby, and in 32 patients (11,4%) a computed 
tomography (CT) angiography of the aorta, for the detection of aortic dimension, was 
performed.   
Doppler echocardiography 
 Transthoracic Doppler echocardiography was performed by expert echocardiographers 
in ACHD using a 3.5 MHz transducer including second harmonic imaging. In all exams 
left atrium and left ventricular dimensions were measured, calculating left ventricular 
mass. Ascending aortic dimensions were measured, with the inner-edge-to-outer-edge 
method, for evaluation of aortic distension in the parasternal long axis view and calculated 
as (end-systolic diameter – end-diastolic diameter)/(end-diastolic diameter) and aortic 
distensibility, defined as (aortic distension)/(systolic blood pressure – diastolic blood 
pressure). For evaluation of left ventricular systolic function, Simpson formula was used. 
Diaphragmatic aorta dimension and pulsed Doppler flow velocity signal were also 
obtained. Aortic flow in the CoA site by both pulsed and continuous wave Doppler was 
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measured, to search for presence or absence of a diastolic tail in the flow velocity curve. 
Aortic arch diameter and aortic diameter at CoA site were measured using the inner-edge-
to-inner-edge method, and. Pulse wave velocity (PWV) was evaluated by (center-line 
derived lenght of the aorta from aortic leaflet point to diaphragmatic aorta, assessed by 
CMR or CT))/(time delay between diaphragmatic foot wave and aortic valve foot wave. 
Diaphragmatic and aortic valve foot wave were obtained by pulsed wave Doppler, 
positioned to distal diaphragmatic aorta and closing point of aortic valve respectively). 
Aortic stiffness parameters were measured offline by FM. All other measurements were 
calculated online and data were collected retrospectively. 
Cardiac magnetic resonance imaging (CMR) and computed tomography (CT) 
Study patients were examined using a 1.5 T or a 3 T whole-body clinical MRI 
system with cardiac synchronization by ECG electrodes. In 27 patients only a MR-
angiography for the evaluation of aortic dimensions was performed. For all the other 
patients, ventricles were imaged from the base towards the apex during end-expiratory 
breath-holds by a stack of retrospectively ECG-triggered SSFP-cine sequence acquisitions. 
End-diastolic and end-systolic contours were manually traced for each slice offline to 
determine left ventricular volumes and mass according to the modified Simpson’s rule 
(disk summation). MR aortography using time-adjusted contrast medium injection was 
used to assess aortic arch and descending aortic geometry, diameter and presence or 
absence of pseudoaneurysm or restenosis at CoA repair site. Reconstructed aortic 3D 
volumes were used for offline centerline assessment of the aortic length between the 
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ascending (sinotubular junction site) and diaphragmal aorta for PWV calculations. 
Retrospectively gated steady-state free procession cine CMR images of the aortic arch, 
along with the ascending, transverse, descending and diaphragmatic aorta were routinely 
undertaken. Throughplane phase contrast flow measurements were acquired during breath-
hold and in retrospectively ECG-gating technique in the ascending, diaphragmal and 
descending aorta at the CoA repair site and in patients with a hypoplastic arch. Aortic 
distension of the ascending aorta was calculated as (maximum systolic area – maximum 
diastolic area)/(maximum diastolic area). Aortic distensibility of the ascending aorta was 
defined as (aortic distension)/(systolic blood pressure – diastolic blood pressure). PWV 
was calculated as (length of the aorta, from sinotubular junction to diaphgramatic aorta, 
derived from the MR-aortography)/(time delay between diaphragmatic foot wave and 
ascending aorta foot wave, derived from flow velocity measurements in the ascending and 
descending aorta). Measurements of aortic distension, aortic distensibility and PWV were 
calculated offline by FM.  
 CT scan was performed in 32 patients who had contraindications to perform CMR. 
Patients were examined while supine, taking images extending from the base of the neck to 
the diaphragm, using retrospective ECG-gated cardiac CT scanning. A 64-slices CT-scan 
was used, with a slice thickness of 1 mm and a reconstruction interval of 0.75 mm. A 3D 
reconstruction of the complete aorta was performed to obtain the complete length of the 
aorta, allowing measurement of the diameter of aorta from ascending to diaphragmatic 
portion.  
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Statistical analysis 
 Categorical variables were reported as percentages. Continuous variables were 
reported as mean ± standard deviation (SD), and non-normally distributed continuous 
variables were presented as median and interquartile range (IQR). For comparison of 
continuous variables among the different groups of dippers and non-dippers, a factorial 
analysis of variance was used. Univariate Cox proportional hazard regression model was 
used to assess the association between clinical, echocardiographic and CMR variables and 
the outcomes. Due to a small number of non-dippers subjects, only variables with p < 0.05 
at univariate analysis were included as covariates in the multivariate Cox regression  
models to test which variables were independently associated with the events. For the 
events with a low number of events, two multivariate models were applied, considering 
clinical, demographic or imaging variables statistical significant at previous univariate 
analysis. Also for the multivariate analysis, statistical significance was defined for a p 
value < 0.05. Hazard ratios and their 95% confidence intervals were presented. Statistical 
analysis was performed with IBM SPSS Statistics v25.0 (Armonk, New York, United 
States of America).   
 
Results 
 Two-hundred and eighty patients (112 females, 40%), mean age of 33,6 ± 13,2, were 
included in the study. Baseline characteristics of the patients are reported in table 1. In this 
199 
 
 
 
 
 
cohort, the more prevalent type of first intervention was the end-to-end anastomosis (64%), 
followed by stenting procedure (14%) (figure 1). One-hundred and eighty-seven patients 
had a concomitant bicuspid aortic valve (67%) and hypoplastic aortic arch (defined as a 
diameter of less than 50% of the diameter of the ascending aorta) (7,17) was present in 132 
patients (47%). One-hundred and thirty-four patients were under anti-hypertensive 
treatment (48%) (a single agent was given to 38 patients, dual therapy was given to 54 
patients, a triple therapy to 31 patients and 11 patients gave 4 anti-hypertensive agents). 
After a mean follow-up period of 20,1 ± 13,1 years, residual arterial hypertension was 
found in 137 patients (49%), nocturnal impaired blood pressure response in the whole 
population was found in 45 patients (16%), and nocturnal impaired blood pressure  
response in normotensive patients was found only in 14 patients (5%) (table 2, figure 2). 
Comparing in the whole population the nocturnal blood pressure response, there were no 
differences between dippers and non-dippers subjects for demographic, clinical, 
echocardiographic, cardiac magnetic resonance and aortic stiffness parameters (table 3).  
 Results of the univariate and multivariate Cox proportional hazard regression model 
are reported in tables 4-6. By multivariate Cox regression analysis, male patients, (HR 
0.409, 95% CI 0.240-0.698, p = 0.001), patients with an older age (HR 0.874, 95% CI 
0.837-0.913, p < 0.001), patients of 8 years of age or older at the age of first CoA repair 
(HR 1.184, 95% CI 1.133-1.238, p < 0.001), and patients with a higher continue wave 
Doppler at CoA site (HR 1.005, 95% CI 1.001-1.010, p = 0.016), resulted at higher risk of 
residual arterial hypertension. Considering ABPM profile, in non-dippers hypertensive and 
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normotensive, older age (HR 0.942, 95% CI 0.910-0.975, p = 0.001 for the whole 
population; HR 0.871, 95% CI 0.790-0.961, p = 0.006 for normotensive patients) and the 
surgical creation of an extra-anatomic aortic ascending-to-descending bypass (EAADB) 
(HR 7.446, 95% CI 1.412-39.281, p = 0.018 for the whole population; HR 14.169, 95% CI 
1.885-106.486, p = 0.010 for normotensive patients) impacted on the abnormal nocturnal 
blood pressure response. In addition, also stenting procedure, in the whole population of 
non-dippers, predicted an abnormal nocturnal blood pressure response (HR 8.377, 95% CI 
2.505-28.012, p = 0.001). None of the other echocardiographic and CMR parameters, nor 
aortic stiffness, resulted predictors of residual arterial hypertension, or of impaired 
nocturnal blood pressure response at multivariate analysis. 
Discussion   
 This multicentric study, conducted on 280 patients from 3 Swiss centers, showed a 
high prevalence of residual hypertension (49%) in a cohort of adult patients with repaired 
CoA. Furthermore, there is also a quite high prevalence (16%) of impaired nocturnal blood 
pressure response, evaluated by ABPM. Moreover, evaluating predictor parameters of 
impaired blood pressure profile in this cohort, several clinical, surgical and imaging 
(considering also aortic stiffness) parameters play a role in predicting hypertensive profile. 
However, adjusting these parameters in a multivariate model, only male patients, patients 
older at follow-up, or older at the age of CoA repair have significantly more hypertension, 
meanwhile, an older age, and two types of operation (stenting procedure, or EAADB) 
resulted predictors of impaired nocturnal blood pressure profile. 
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 These results are quite in line with previous studies, where was found a high 
prevalence of residual hypertension, most of all in older patients and in patients older at 
time of intervention. In some previous studies (19,20), was described a lower prevalence of 
residual hypertension (32% and 30% respectively). Toro-Salazar et al (21), in a previous 
study, evaluated a smaller cohort of repaired CoA patients (92 patients), finding also them 
a lower prevalence of hypertension (35%), with an increased hypertensive risk in patients 
older than 10 years at time of operation. These results are similar with the results of our 
study, where we found a higher hypertensive risk in patients older than 8 years at time of 
operation, with a quite similar prevalence of hypertension, but with a larger cohort in our  
study. On the other hand, Hager et al (10), differently from our study, found a more 
prevalent residual hypertension (55%) in a cohort of 245 adult operated CoA patients 
without restenosis, with a similar high prevalence in patients older at intervention and at 
follow-up, and male patients. The higher prevalence found in their study should be due to 
the selection of hypertensive patients, where they defined hypertension on ambulatory 
blood pressure as > 133/78 mmHg. Also Brown et al (6), in a more recent study, evaluated 
a larger cohort (819 patients), finding a prevalence of hypertension from 40% up to 70%, 
based on the follow-up time. In this study, they defined as predictor of residual 
hypertension, only the older age at time of CoA repair. These results differ from ours 
considering the prevalence of residual hypertension, that is higher (maybe due to the larger 
cohort evaluated by Brown et al), but they defined like us, a role of older age at time of 
operation, but without finding any other predictors. A systematic review of Canniffe et al 
(22), made on 26 studies, defined a prevalence of residual hypertension in operated CoA 
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patients of 32,5% (range 25-68%), considering as factor influencing the presence of 
residual hypertension age at time of surgery, age at follow-up, and type of intervention. 
The different prevalence found in our study should be explained by the different blood 
pressure cut-off used by the other authors included in the systematic review of Canniffe et 
al. On the other hand, similarly to our study, they found a role of older age in predict 
residual arterial hypertension, but differently from us, they defined a role of type of 
intervention, that in our analysis resulted only at the univariate analysis for end-to-end 
anastomosis, stenting procedure, and subclavian flap repair procedure, but that weren’t  
confirmed at the multivariate model. Finally, in a more recent study, Rinnström, et al (23), 
in a cohort of 653 operated CoA patients, found a similar prevalence of residual arterial 
hypertension of our study (52%), with an association (as in our study) with male sex, older 
age at follow-up and older age at time of intervention.  
 On the other hand, considering the nocturnal blood pressure response, evaluated by 
ABPM, there are no data in literature, in particular regarding non-dipper profile, both in 
hypertensive and normotensive patients. In our study, we found a prevalence of 16% of 
general non-dippers, and a prevalence of 5% of normotensive non-dippers, with a 
correlation of them with older age, stenting procedure and EAADB for all non-dippers, 
adding also aortic distension and distensibility at univariate analysis for normotensive non-
dippers, not confirmed by multivariate model. These results are very impressive, and more 
studies are warranted to confirm these data, also to define an additional role of ABPM in 
the follow-up of repaired CoA patients, to find concealed hypertension in these patients.  
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Limitations 
This is a retrospective study, with a relative small sample size, and a small number 
of ABPM, that was performed only in a little part of normotensive patients. 
 
Conclusions 
 In a cohort of 280 operated CoA patients, from 3 different centers, was found a high 
prevalence of residual hypertension, with a role of older age at follow-up and of an age > 8  
years at time of intervention in define the presence of hypertension. Moreover, this is the 
first study evaluating the nocturnal blood pressure profile by ABPM, finding a 16% 
prevalence of non-dippers in operated CoA patients. 
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Table 1. Baseline characteristics of patients 
 Patients (n = 280)  
Age (years) (range) 33,6 ± 13,2 (17,1-84,5) 
Female  112 (40%) 
BSA (m
2
) 1,84 ± 0,23 
BMI (Kg/m
2
) 25,4 ± 10,2 
Age at first intervention (years) (range) 3,6 (0,1-59,7) 
Systolic blood pressure (mmHg) 129 ± 14 
Diastolic blood pressure (mmHg) 73 ± 11 
Leg blood pressure (mmHg) 124 ± 16 
Type of intervention  
     End-to-end anastomosys  181 (65%) 
     Stenting  39 (14%) 
     Aortic patch plasty  22 (8%) 
     Subclavian flap-repair  22 (8%) 
     Ascending-to-descending bypass  11 (4%) 
     Graft interposition  5 (2%) 
Bicuspid aortic valve  187 (67%) 
Hypoplastic aortic arch  132 (47%) 
Gothic arch  37 (13%) 
Ventricular septal defect  57 (20%) 
Other congenital heart disease  52 (19%) 
Turner syndrome  10 (4%) 
Anti-hypertensive treatment  134 (48%) 
     Beta-blockers  67 (50%) 
     ACE-i  51 (38%) 
     ARBs  66 (49%) 
     Calcium-antagonists  56 (42%) 
     Diuretics  42 (31%) 
     Alfa-blockers  1 (0,7%) 
BSA: body surface area; BMI: body mass index; ACE-i: angiotensin converting enzyme 
inhibitors; ARBs: angiotensin II receptor blockers. 
Categorical variables reported as absolute numbers and percentages. Continuous variables 
reported as mean ± standard deviation, and non-normally distributed continuous variables 
presented as median and range. 
 
 
 
 
209 
 
 
 
 
 
Table 2. blood pressure profile prevalence 
 Patients (n = 280) 
Blood pressure profile  150 (54%) 
     Residual arterial hypertension  137 (49%) 
          Sex (F/M)  40/97 
     Non-dippers  45 (16%) 
     Normotensive non-dippers  14 (5%) 
F: female; M: male. 
Categorical variables reported as absolute numbers and percentages. Continuous variables 
reported as mean ± standard deviation, and non-normally distributed continuous variables 
presented as median and interquartile range (IQR). 
 
 
 
Table 3. Differences between Dipper subjects and non-Dipper subjects  
 Non Dipper subjects 
(n=45) 
Dipper subjects 
(n=96) 
p 
value 
Age (years) 34,15 ± 13,32 32,8 ± 13,92 0.587 
BMI (kg/m
2
) 27,16 ± 5,42 24,96 ± 3,93 0.007 
Systolic blood 
pressure (mmHg) 
134,42 ± 15,09 133,31 ± 12,7 0,648 
Diastolic blood 
pressure (mmHg) 
73,89 ± 12,28 72,52 ± 11,82 0,527 
Leg systolic blood 
pressure (mmHg) 
129,52 ± 18,28 124,46 ± 13,79 0.107 
Echo LVEDd (mm) 49,4 ± 5,06 48,65 ± 6,36 0.496 
Echo LVESd (mm) 31,54 ± 4,19 30,2 ± 5,3 0.155 
Echo LV mass (g/m
2
) 102,72 ± 31,2 102,16 ± 36,32 0.935 
Echo LVEF (%) 60,75 ± 6,82 62,74 ± 6,36 0.097 
Echo aortic distension 0,141 ± 0,049 0,146 ± 0,057 0.618 
Echo aortic 
distensibility (mmHg
-
1
x10
-3
) 
0,0026 ± 0,0014 0,0026 ± 0,0015 0.857 
Echo PWV (m/s) 8,88 ± 3 10,46 ± 6,04 0.293 
CMR LVEDV (ml) 165,54 ± 39,98 156,39 ± 39,32 0.294 
CMR LVESV (ml) 63,71 ± 19,58 57,52 ± 16,79 0.161 
CMR LVEF (%) 61,65 ± 5,8 62,85 ± 7,21 0.411 
CMR LV mass (g/m
2
) 67,46 ± 18,92 75,03 ± 22,64  0.131 
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CMR aortic distension 0,54 ± 0,31 0,44 ± 0,2 0.218 
CMR aortic 
distensibility (mmHg
-
1
x10
-3
) 
0,0093 ± 0,0058 0,0074 ± 0,0038 0.185 
CMR PWV (m/s) 7,18 ± 2,63 10,32 ± 7,54 0.226 
BMI: body mass index; LVEDd: left ventricle end-diastolic diameter; LVESd: left 
ventricle end-systolic diameter; LV: left ventricular; LVEF: left ventricle ejection fraction; 
PWV: pulse wave velocity; CMR: cardiac magnetic resonance; LVEDV: left ventricle end-
diastolic volume; LVESV: left ventricle end-systolic volume. 
 
 
 
Table 4. Cox analysis for residual arterial hypertension 
Univariate analysis residual arterial hypertension 
Variables HR 95%CI p value 
Age 0.965 0.949-0.981 <0.001 
Sex 0.486 0.335-0.704 <0.001 
Age of first CoA 
repair 
1.033 1.018-1.047 <0.001 
End-to-end 
anastomosis 
procedure 
0.680 0.478-0.967 0.032 
Stenting 
procedure 
6.557 3.724-11.545 <0.001 
Subclavian flap 
repair procedure 
0.361 0.147-0.885 0.026 
Presence of 
hypoplastic 
aortic arch 
1.727 1.219-2.446 0.002 
Echo CW peak 
at CoA site 
1.007 1.003-1.010 <0.001 
CMR aortic arch 
diameter 
0.936 0.894-0.980 0.005 
CMR diastolic 
tail at CoA site 
3.939 1.582-9.807 0.003 
CMR diastolic 
tail at 
diaphragmatic 
3.716 1.604-8.608 0.002 
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aorta 
Multivariate analysis residual arterial hypertension 
Variables HR 95%CI p value 
Age 0.874 0.837-0.913 <0.001 
Sex 0.409 0.240-0.698 0.001 
Age of first CoA 
repair 
1.184 1.133-1.238 <0.001 
Echo CW peak 
at CoA site 
1.005 1.001-1.010 0.016 
HR: hazard ratio; CI: confidence intervals; CoA: aortic coarctation; CW: continue wave; 
CMR: cardiac magnetic resonance. 
 
 
 
Table 5. Cox analysis for non-dipper ABPM profile 
Univariate analysis non-dipper ABPM profile 
Variables HR 95%CI p value 
Age 0.950 0.920-0.980 0.001 
End-to-end 
anastomosis 
procedure 
0.531 0.292-0.966 0.038 
Stenting 
procedure 
11.490 4.290-30.775 <0.001 
Ascending-to-
descending 
bypass 
procedure 
5.485 1.265-23.777 0.023 
Multivariate analysis non-dipper ABPM profile 
Variables HR 95%CI p value 
Age 0.942 0.910-0.975 0.001 
Stenting 
procedure 
8.377 2.505-28.012 0.001 
Ascending-to-
descending 
bypass 
procedure 
7.446 1.412-39.281 0.018 
ABPM: ambulatory blood pressure monitoring; HR: hazard ratio; CI: confidence intervals. 
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Table 6. Cox analysis for normotensive non-dipper ABPM profile 
Univariate analysis normotensive non-dipper ABPM profile 
Variables HR 95%CI p value 
Age 0.902 0.833-0.978 0.012 
End-to-end 
anastomosis 
procedure 
0.271 0.093-0.788 0.016 
Stenting 
procedure 
8.285 1.809-37.948 0.006 
Ascending-to-
descending 
bypass 
procedure 
13.906 2.875-67.251 0.001 
Echo aortic 
distension  
101218.837 8.922-
1148304968 
0.016 
Echo aortic 
distensibility 
>100 1->1000 0.026 
CMR aortic 
distensibility 
<100 1->1000 0.036 
Multivariate analysis normotensive non-dipper ABPM profile 
Variables HR 95%CI p value 
Age 0.871 0.790-0.961 0.006 
Ascending-to-
descending 
bypass 
procedure 
14.169 1.885-106.486 0.010 
ABPM: ambulatory blood pressure monitoring; HR: hazard ratio; CI: confidence intervals; 
CMR: cardiac magnetic resonance. 
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Figures 
 
 
Figure 1. Blood pressure profile prevalences 
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Figure 2. Distribution of type of CoA intervention 
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Abstract 
Introduction: Aortic and arterial stiffness are directly related to increased morbidity and 
mortality and are associated with varies cardiovascular risk factors, and have been shown 
to be increased in CoA patients late after repair. The aim of this study is to assess aortic 
stiffness by echocardiography and CMR and to compare these two techniques. 
Methods: We retrospectively evaluated 119 adult patients with repaired CoA. All patients 
underwent to an echocardiographic exam, and of 119 patients, 109 underwent to a cardiac 
magnetic resonance (CMR) exam for the assessment of aortic distension, aortic 
distensibility and pulse wave velocity (PWV). 
Results: Seventy-four patients (62%) were male, mean age 31,7 ± 13,4 years. Impaired 
aortic stiffness was found in 55 patients (46%). Comparing the 3 parameters of aortic 
stiffness by echocardiography and CMR, only for PWV resulted a correlation between the 
2 techniques (p < 0.001, 95% CI -1.390-0.233). 
Conclusions: There is a good correlation between echocardiography and CMR for the 
detection of PWV in adult patients with repaired CoA. This correlation was not found for 
aortic distension and aortic distensibility.  
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Introduction 
 Patients with aortic coarctation (CoA), even after successful intervention, remain at 
high cardiovascular risk, most related to residual arterial hypertension. Different 
pathogenic mechanisms can play a role in define abnormal blood pressure response in 
these patients, bringing to an elevated risk for cardiovascular events (1). One of these is 
arterial stiffness, one of the earliest detectable manifestations of adverse structural and 
functional changes within the vessel wall (2).  
Aortic and arterial stiffness are directly related to increased morbidity and 
mortality, both due to themselves, but also for their association with varies cardiovascular 
risk factors (3-5). Nevertheless, aortic and arterial stiffness play an important role in 
predict cardiovascular morbidity and mortality blood-pressure independently (6). Aortic 
stiffness by means of impaired ascending aorta and aortic arch distension and 
distensibility, but not impaired descending aorta distension and distensibility, has been 
shown to be increased in CoA patients late after repair (7-8). It has often been associated 
with aortic arch anomalies like gothic aortic arch (1,7). Assessment of aortic stiffness can 
be made by measurement of parameters such as aortic distension, aortic distensibility and 
pulse-wave velocity (PWV), and has been validated in the last 10 years (9-11), with the 
definition of normal reference values, also in children and young adults (2,12). These 
parameters can be analyzed in the ascending and diaphragmal aorta by echocardiography 
and CMR data with through-plane phase contrast flow velocity measurements.  
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 The aim of this study was to assess aortic stiffness (aortic distension, aortic 
distensibility and PWV) by echocardiography and CMR and to compare these two 
techniques, to define also a cost-effectiveness strategy to follow in adult patients with 
repaired CoA. 
 
Methods 
Study patients 
 We retrospectively evaluated 119 adult patients with repaired CoA from a single 
center belonging to the Swiss Adult Congenital HEart disease Registry (SACHER) (13). 
Data from the most recent clinical evaluation with right cubital and leg office blood 
pressure measurements (left arm measurements in patients with a right-sided aortic arch), 
ambulatory 24-hour blood pressure measurement of the right arm (left arm measurements 
in patients with a right-sided aortic arch), and type and dosage of the current anti-
hypertensive medication were recorded and included into our analysis. All patients 
underwent to an echocardiographic exam, and of 119 patients, 109 underwent to a CMR 
exam (10 patients did not perform CMR due to the presence of a pacemaker or for 
claustrophoby). In 5 patients (4%) an aortic angiography by computed tomography (CT)-
scan was performed. 
Echocardiographic assessment of aortic stiffness 
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 Transthoracic Doppler echocardiography was performed using an Acuson Sequoia C 
512 (Acuson Corporation, Siemens, Mountain View, CA, USA) or Philips IE 33 
ultrasound systems (Philips, Amsterdam, The Netherlands) with a 3.5 MHz transducer 
including second harmonic imaging. All echocardiography images and clips were stored 
off-line (Philips IntelliSpace Cardiovascular, Version 2.3, Best, Netherlands). In 
parasternal long-axis view, were defined aortic dimensions, in particular ascending aorta, 
for the evaluation of aortic distension, defined as (systolic diameter – diastolic 
diameter)/(diastolic diamenter) and aortic distensibility, defined as (aortic 
distension)/(systolic blood pressure – diastolic blood pressure). Ascending aorta was 
measured using the inner-edge-to-outer-edge method. Aortic arch diameter and aortic 
diameter at CoA site were measured using the inner-edge-to-inner-edge method. Pulse 
wave velocity (PWV) was evaluated by (center-line derived lenght of the aorta from aortic 
valve closing point to diaphragmatic aorta, assessed by CMR or CT))/(time delay between 
diaphragmatic foot wave and aortic valve foot wave. Diaphragmatic and aortic valve foot 
wave were obtained by pulsed wave Doppler, positioned to distal diaphragmatic aorta and 
closing point of aortic valve respectively). For all measurements, final values were 
obtained after averaging over three cardiac cycles. Intra-observer variability for all the 
echocardiographic parameters of RV function was calculated in 30 randomly selected 
exams. 
CMR assessment of aortic stiffness 
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 Study patients were examined using a 1.5 T (Magnetom Symphony) or a 3 T 
(Magnetom Trio, both from Siemens Medical Solutions, Erlangen, Germany) whole-body 
clinical MRI system with cardiac synchronization by ECG electrodes. MR aortography 
using time-adjusted contrast medium injection was used to assess aortic arch. 
Retrospectively gated steady-state free procession cine CMR images of the aortic arch, 
along with the ascending, transverse, descending and diaphragmatic aorta were routinely 
undertaken. Through plane phase contrast flow measurements were acquired during 
breath-hold and in retrospectively ECG-gating technique in the ascending, diaphragmal 
and descending aorta at the CoA repair site and in patients with a hypoplastic arch. Aortic 
distension of the ascending aorta was calculated as (maximum systolic area – maximum 
diastolic area)/(maximum diastolic area). Aortic distensibility of the ascending aorta was 
defined as (aortic distension)/(systolic blood pressure – diastolic blood pressure). PWV 
was calculated as (length of the aorta, from sinotubular junction to diaphgramatic aorta, 
derived from the MR-aortography)/(time delay between diaphragmatic foot wave and 
ascending aorta foot wave, derived from flow velocity measurements in the ascending and 
descending aorta). Measurements of aortic distension, aortic distensibility and PWV were 
calculated offline by FM.  
CT scan for the evaluation of aorta 
 CT scan was performed in 5 patients who had contraindications to perform CMR. 
Patients were examined while supine, taking images extending from the base of the neck to 
the diaphragm, using retrospective ECG-gated cardiac CT scanning. A 64-slices CT-scan 
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was used, with a slice thickness of 1 mm and a reconstruction interval of 0.75 mm. A 3D 
reconstruction of the complete aorta was performed, obtaining the entire length of the aorta 
from the ascending to the diaphragmal aorta, used for the calculation of PWV by echo 
Doppler flow profiles. 
Statistical analysis 
 Categorical variables were reported as percentages. Continuous variables were 
reported as mean ± standard deviation (SD), and non-normally distributed continuous 
variables were presented as median and interquartile range (IQR). T-test for independent 
samples was used to compare PWV in Gothic arch and aortic arch with normal shape. 
Comparisons between echocardiographic and CMR aortic stiffness (aortic distension, 
aortic distensibility and PWV) were performed using an un-paired t-test or the Mann-
Whitney test for non-normally distributed variables. Measurement of reproducibility was 
evaluated calculating the interclass correlation coefficient (ICC), for the assessment of 
observer agreement, with a cut-off value proposed by Burdock et al. (14) up than 0.75 to 
signify good agreement. In all analyses, the null hypothesis was rejected for p values < 
0.05. Statistical analysis was performed with IBM SPSS Statistics v25.0 (Armonk, New 
York, United States of America). 
 
Results 
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Seventy-four patients (62%) were male, mean age 31,7 ± 13,4 years. Baseline 
characteristics of patients are shown in table 1. In this cohort, the more prevalent type of 
first intervention was the end-to-end anastomosis (72; 61%), followed by stenting 
procedure (18; 15%) and aortic patch plasty procedure (16; 13%) (figure 1). Seventy-seven 
patients had a concomitant bicuspid aortic valve (65%) and hypoplastic aortic arch  
(defined as a diameter of less than 50% of the diameter of the ascending aorta) (15,16) was 
present in 75 patients (63%), and Gothic arch was present in 25 patients (21%). Sixty-six 
patients were under anti-hypertensive treatment (55%).  
Aortic distension and distensibility were detected by echocardiography and CMR in 
100 patients (84%), meanwhile, PWV was detected in 80 patients (67%). Considering a 
mean normal value based on different values of aortic stiffness per aorta section studied, 
impaired aortic stiffness was found in 55 patients (46%). Comparing PWV between 
patients with Gothic arch (14 patients), and patients with normal aortic arch shape (66 
patients), there was no difference between the groups (normal shape PWV 11 ± 9.3 vs 
Gothic arch PWV 9.6 ± 5.7, p = 0.446). Comparing the 3 parameters of aortic stiffness by 
echocardiography and CMR, only for PWV resulted a correlation between the 2 techniques 
(p < 0.001, 95% CI -1.390-0.233) (figure 2), instead for aortic distension and distensibility, 
the correlation was not significant (p = 0.985, 95% CI -0.359/-0.261; p = 0.142, 95% CI -
0.006/-0.004, respectively) (table 2). 
ICC for intra-observer variability for aortic distension, aortic distensibility and 
PWV evaluated by echocardiography were as follows: 0.973, 0.963, 0.865, respectively.  
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Discussion 
 This study made on 119 patients showed a high rate of impaired aortic stiffness in a  
population of adult with repaired CoA. PWV is defined as gold standard for the assessment 
of aortic stiffness (17), and can be easily measured by echocardiography and CMR. In Our 
study, for PWV, but not for aortic distension and aortic distensibility, a correlation between 
echocardiography and CMR measurement was found.  
Several previous studies have shown a high prevalence of impaired aortic stiffness 
in patients with repaired CoA. In particular, three studies (1,7,18) described an impaired 
aortic stiffness in repaired CoA, in particular with a high rate in presence of Gothic arch. 
Ou et al (7), in a cohort of 63 repaired CoA, with three types of aortic arch (Gothic, Crenel, 
and Romanesque) and 63 controls, evaluating aortic distensibility by CMR, found a worst 
aortic stiffness in CoA patients, and also in Gothic arch when compared with the other arch 
morphologies. The same author (18), studied a population of 55 repaired CoA (20 Gothic 
arches and 35 Romanesque arches) and 20 control subjects. In this study was evaluated not 
only aortic distensibility, but also PWV by CMR. They found a significantly lower aortic 
distensibility and a higher PWV in Gothic arch when compared with control subjects and 
Romanesque arch. This difference was not found between Romanesque arch and healthy 
controls. Also Donazzan et al (1), in a population of 26 repaired CoA, compared aortic 
distensibility by CMR in 6 patients with Gothic arch morphology and 20 patients with 
normal arch shape, finding a significantly lower aortic distensibility in Gothic arch. These 
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three studies show a role of aortic arch morphology in define an impaired aortic stiffness, 
with particular attention on Gothic arch. In our study, differently from them, there wasn’t a 
difference between Gothic arch and normal shape, not confirming the role of aortic arch  
morphology in define an impaired aortic stiffness. However, in our study there isn’t a 
control population, so the only difference is in repaired CoA patients. Based on this 
assumption, other studies (19,20) have described an impaired aortic stiffness in patients 
with repaired CoA, independently from aortic arch shape. Ou et al (19), compared a 
population of 40 normotensive subjects after CoA repair and 20 control subjects, 
describing in repaired CoA patients a significantly reduced aortic stiffness and an increased 
PWV, both evaluated by CMR. In the same year, Vitarelli et al (20), compared 26 adult 
normotensive patients who had successful CoA repair in infancy and 24 control subjects. 
In this study, aortic stiffness was evaluated by echocardiography. They found an increased 
aortic stiffness in patients, compared to control subjects. These two studies confirm our 
hypothesis of impaired aortic stiffness in adult patients after CoA repair (in our population 
we had a 46% prevalence of impaired aortic stiffness), but differently from us, they 
compare aortic stiffness of repaired CoA with healthy subjects.  
Finally, our study is the first in comparing aortic stiffness measurement between 
echocardiography and CMR in adult patients with repaired CoA. Previous studies 
(16,21,22) have evaluated different ways to detect aortic stiffness, also comparing CMR 
with less expansive methods. Giannattasio et al (21), measured aortic distensibility and 
PWV by tonometry and CMR in a population of 28 normotensive subjects. In this study 
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was found a significant correlation between aortic distensibility evaluated by tonometry 
and CMR, while no correlation was found for PWV. Our results are opposite with those of 
Giannattasio et al, in fact we found a correlation only for PWV. Differently from them, we  
have a larger population, and all our patients are operated for CoA. More recently, 
Feistritzer et al (17), Compared in 40 volunteers the measurement of PWV by oscillometric 
method and CMR. In line with our study, they found a correlation between the 2 
methodology of measurement. However, in our study we evaluated also aortic distension 
and aortic distensibility, and our study was performed on repaired CoA. Finally, the same 
author (22), evaluated PWV by oscillometric method and CMR in 60 reperfused 
myocardial infarction, finding also in this case a good correlation between oscillometric 
method and CMR for the measurement of PWV. Although also these results are in line 
with our results, there is a different type of population, where our study is the only one 
considering comparison between CMR and an ultrasound method to evaluate aortic 
stiffness in patients with repaired CoA.   
 
Limitations 
 This study is a retrospective single center study, made on a relative small population. 
Moreover, aortic stiffness, and in particular PWV was not performed in the whole 
population. 
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Conclusions 
 This is the first study evaluating the comparison between aortic stiffness measured by  
ultrasound and CMR in a cohort of repaired CoA patients. In a population of 119 patients, 
was found a good correlation between CMR and echocardiography in measuring PWV, but 
not for aortic distension and aortic distensibility. However, a prospective study is 
warranted to confirm these data. 
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Table 1. Baseline characteristics of patients 
 Patients (n = 119)  
Age (years) (range) 31,7 ± 13,4 (17,1-84,5) 
BSA (m
2
) 1,8 ± 0,2 
BMI (Kg/m
2
) 24,8 ± 3,8 
Age at first intervention (years) (range) 4,2 (0,1-59,1) 
Type of intervention  
     End-to-end anastomosys  72 (61%) 
     Stenting  18 (15%) 
     Aortic patch plasty  16 (13%) 
     Subclavian flap-repair  7 (6%) 
     Ascending-to-descending baypass  4 (3%) 
     Graft interposition  2 (2%) 
Bicuspid aortic valve  77 (65%) 
Hypoplastic aortic arch  75 (63%) 
Gothic arch  25 (21%) 
Ventricular septal defect 27 (23%) 
Other congenital heart disease  15 (13%) 
     Atrial septal defect  3 (20%) 
     Transposition of the great arteries  3 (20%) 
     Aorto-pulmonary window  2 (13%) 
     Congenital valvular aortic stenosis  2 (13%) 
     Double orifice mitral valve  1 (7%) 
     Severe mitral valve prolapse  1 (7%) 
     Ebstein syndrome  1 (7%) 
     Tetralogy of Fallot  1 (7%) 
     Double inlet left ventricle  1 (7%) 
Turner syndrome  2 (2%) 
Anti-hypertensive treatment  66 (55%) 
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BSA: body surface area; BMI: body mass index.  
Categorical variables reported as absolute numbers and percentages. Continuous variables 
reported as mean ± standard deviation, and non-normally distributed continuous variables 
presented as median and range. 
 
 
Table 2. Correlation between PWV, aortic distension and aortic distensibility evaluated by 
echocardiography and cardiac magnetic resonance. 
 Echocardiographic 
assessment (mean ± 
SD) 
Cardiac magnetic 
resonance 
assessment (mean 
± SD) 
P value 
PWV (m/s) 10,28 ± 7,15  10,86 ± 8,82 < 0.001 
Aortic Distension 0,145 ± 0,064   0,455 ± 0,232 0.985 
Aortic 
Distensibility 
(mmHg
-1
x10
-3
) 
0,003 ± 0,0014   0,008 ± 0,005 0.142 
SD: standard deviation; PWV: pulse wave velocity. 
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Figures 
 
 
Figure 1. Distribution of type of CoA intervention 
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Figure 2. Bland Altman plot for pulse wave velocity 
 
 
 
 
 
 
 
Mean 
D
ff
er
en
ce
 
235 
 
 
 
 
 
CHAPTER 11. 
Discussion and conclusion 
Since many years, well known is the role of some non-conventional risk factors, which can 
influence CV risk. In particular, there is a iatrogenic effect of some drugs, that increase CV 
risk, leading to an atherosclerotic burden in several patients (Chapter 2). In particular, 
patients with rheumatic disease, patients with chronic pain, are exposed (many times since 
childhood) to a major CV risk using NSAIDs chronically. For this reason, current 
guidelines recommend caution on the use of these agents, in particular in patients with a 
previous history of CV disease. However, there is a range of safety for some of these 
drugs, in particular naproxen have shown a lower risk for CV side effects.  
A great part of CV risk is subclinical, especially when it starts during childhood. This 
could lead to the use of non-invasive imaging techniques, to early detect coronary artery 
disease (Chapter 3). And now, it is recognized the role of non-invasive imaging, especially 
in low-to-intermediate pre-test probability of coronary artery disease. On the other hand, in 
the definition of early detection of clinical and subclinical coronary artery disease, but also 
of CV risk, it is well known the role of IMT and EAT, that reflect the CV burden of risk in 
several patients. In more detail, while IMT is recognized also by guidelines as a real CV 
risk factor (although called “non-conventional”), regarding EAT, that is an emerging CV 
risk factor, poor is known about its real role, although today it is considered as visceral fat. 
These two non-conventional risk factors, largely studied in some particular cohort of  
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patients (especially obese patients), today also in HIV patients are often evaluated (Chapter 
7). Increased IMT in HIV patients is widely recognized, meanwhile, poor was known 
about EAT in HIV patients. In Chapter 6, it is described for the first time an increase of 
EAT in HIV children and young adults, compared to healthy subjects. These results, 
together with the increase of IMT in this population, could explain an increased CV risk in 
HIV patients, and in particular, in HIV children and young adults vertically infected. 
Regarding non-conventional CV risk factors again, there are also some metabolic deficit 
involved in CV disease. In particular, one of the most recently studied is Vitamin D 
deficiency (Chapter 6). Vitamin D deficiency should be responsible of atherosclerotic side 
effects and of heart failure development. Vitamin D deficiency or insufficiency generally 
starts since childhood, and this can explain also the cumulative effect of this deficit, 
leading to CV disease. Nevertheless, what is interesting, is the not completely clear role of 
Vitamin D supplementation, which although in some studies is related to an improvement 
of CV risk and disease, in others a real beneficial effect of supplementation was not seen. 
However, modern medicine does not focus only on non-conventional CV risk factors, but 
there is always something new also in traditional CV risk factors. In particular, there is a 
new class of drugs, GLP-1 agonists, which are very effective in the oral treatment of 
diabetes. It is well known that diabetes, at every ages, is one of the most important CV risk 
factors, first for atherosclerotic disease, but also for heart failure (chapter 4). However, 
although there is an effect of GLP-1 agonists on CV disease related to treatment of 
diabetes, the most interesting thing is that GLP-1 agonists reduce all cause and CV 
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mortality, independently from is effects on glycaemia (Chapter 5). This effect is clear on 
macrovascular and microvascular events, but also on heart failure.  
Although the important role of conventional and non-conventional risk factors in 
development of CV disease from childhood to adulthood, the major part of CV disease in 
children are the congenital ones. Thanks to the progress in surgery techniques, a great part 
of CHD arrive to adulthood, so called GUCH. However, there are some forms of CHD, 
which are related to particular genetic disorders, which in a great parte are incompatible 
with life. One of the more typical manifestation of severe CHD is hypertrophic 
cardiomyopathy, which in several cases is related to a specific gene mutation (Chapter 8). 
In more detail, there is a spectrum of genetic disease, called mitochondrial disorders, which 
can often be the cause of hypertrophic cardiomyopathy, and in a great number of cases are 
fatal. Therefore, for these class of patients, the only solution could be the heart transplant 
when feasible.  
Nevertheless, luckily, there is a wide part of CHD that can be treated by surgery, and that 
lead to adulthood. However, GUCH patients develop during the years several CV risk 
factors and CV disease. One of the most common problem related to CHD shunt-related is 
the development of pulmonary hypertension (PH) (Chapter 9). Therefore, in these patients, 
there is a worsening of prognosis year by year, which needs a prompt treatment. In 
particular, the involvement of right heart is very important, and in the follow up of these 
patients, is known the role of the interval changes, in particular for right ventricular 
volumes, on the worse prognosis PH related. 
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Another important “side effect” that can develop in GUCH patients is arterial 
hypertension, especially in operated CoA patients, where there is a wide spectrum of 
possible side effects secondary to the intervention. CoA is a congenital disease of the 
proximal descending aorta defined as a hemodynamic significant aortic narrowing 
(Chapter 10.1, 10.2, 10.3). There are several type of intervention useful to treat CoA, from 
childhood to adulthood, based on the era of the diagnosis. Generally, percutaneous stent 
implantation is the type of intervention used in adults. These patients are generally 
followed up after the intervention, with several exams, such as echocardiography and 
cardiac magnetic resonance for the assessment of ejection fraction, left ventricular 
volumes, diameters of the aorta and presence of diastolic tails, and evaluation of aortic 
stiffness; exercise stress test, with the evaluation of blood pressure profile; ambulatory 
blood pressure monitoring. All these exam are important to detect the presence of several 
outcomes, and to define the potential predictors of endpoints, that can be responsible of a 
bad prognosis in operated CoA patients. In particular, beyond the clinical outcomes in 
these patients, it is important also to consider re-CoA rate, that could require a second 
intervention, and pseudoaneurysm formation, that is a common complication for these 
patients, that in many cases can require a re-intervention. Finally, aortic stiffness can play a 
role in the prognosis of operated CoA patients, in fact well known is that aortic stiffness is 
frequently impaired in these patients, so it should be important also define the best, less 
expensive, and less invasive way to measure it to define prognosis.  
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In conclusion, it is not true that CV disease are a peculiarity of older patients. In fact, there 
are several conventional and non-conventional risk factors, iatrogenic factors and 
metabolic deficit, which starting in childhood, could lead to CV risk and CV disease in 
adulthood. On the other hand, it is not true that CHD are a peculiarity of children, where 
thanks to the progresses in cardiac surgery, a great part of these patients arrives to 
adulthood, needing to be treat as adult patients with CV disease.   
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